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Abstract 
Marine environments represent a rich source of bioactive secondary metabolites that may 
be harnessed for use in a therapeutic context. Two novel compounds, peloruside A and 
laulimalide, isolated from the marine sponges Mycale hentsheli and Cacospongia 
mycofijiensis, respectively, both demonstrate useful pharmacological properties in 
mammalian cells. These compounds share major similarities with microtubule-stabilising 
agents. Like other agents in this class, peloruside A and laulimalide bind to the β-tubulin 
subunit of microtubules, the primary cytoskeletal element of eukaryotic cells. These 
compounds enhance polymerisation dynamics between ternary microtubule structures and 
severely hinder necessary cytoskeletal rearrangements within the cell.  
Over the course of a patient’s treatment, cancerous cells may develop multi-drug resistance 
phenotypes. P-glycoprotein drug efflux pumps play a major role in the development of 
therapy resistance in many cancers, as the current generation microtubule-stabilising agents 
are easily removed from diseased cells by upregulated efflux mechanisms. Unlike agents 
already in clinical application, both peloruside A and laulimalide are poor substrates for 
removal by these mechanisms, making them and their synthetic derivatives interesting as 
potential treatments for drug-resistant tumours. 
Peloruside A and laulimalide exhibit potent nanomolar anti-mitotic activities in vitro and 
arrest cell cycle progression in G2/M phase, leading to cell death – a characteristic mode of 
action among microtubule-stabilising agents. Unlike all known agents in this class, 
peloruside A and laulimalide share a secondary, unique binding region in β-tubulin. In the 
past decade our understanding of this region has developed, revealing a second, unique 
mechanism for stabilisation of microtubules. 
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Using mammalian cells to model physiological tubulin, the present study investigates the 
predicted role of aspartic acid 297 of human βI-tubulin in the binding association of both 
peloruside A and laulimalide. This particular amino acid is predicted to hydrogen bond with 
both compounds, contributing to their activity as stabilisers.  
It was revealed that the introduction of a point mutation in D297 resulted in a small but 
highly consistent resistance phenotype to both compounds, but not to microtubule-
stabilising agents that bind to the traditional, taxoid site on β-tubulin. It was concluded that 
aspartic acid 297 is likely to be one of the amino acids directly involved in the binding 
association of peloruside A and laulimalide to β-tubulin, contributing partial compound 
stabilisation. The rational synthesis of future analogues may benefit from these findings in 
the design of molecules with enhanced interactions at this particular amino acid residue. 
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Chapter 1. Introduction 
1.1 General Introduction 
1.1.1 Bioactive compounds sourced from nature 
Natural products are a particularly valuable source of bioactive compounds for use in a 
therapeutic context as the sheer diversity of biosynthetic processes found throughout nature 
has led to an unparalleled diversity in unique chemical structures (Harvey, Clark et al. 2010, 
Yue, Liu et al. 2010). These compounds often exhibit interesting pharmacological 
properties when extracted from raw biomass, particularly in the case of novel secondary 
metabolites sourced from marine environments (Faulkner, 2002). Through evolutionary 
development over millions of years, organisms produce secondary metabolites with 
exquisite bioactivities against protein targets in living systems.  
 Current techniques in organic chemistry allow the synthesis of vast libraries of novel 
organic structures; however, the majority of these compounds lack significant functional 
activity against biomolecular targets found within living systems (Leach and Hann 2000). 
This leaves synthetic compounds with somewhat limited potential in comparison to the 
exquisite bioactivity of natural products, provided by millions of years of evolutionary 
development against target proteins in living organisms. Active secondary metabolites are 
often produced by microbial organisms with symbiotic relationships to  higher-level host 
organisms (Belarbi, Contreras Gómez et al. 2003) as chemical defence mechanisms against 
predation (Sipkema, Franssen et al. 2005) to support the host organism. Natural compounds 
that exhibit potent activities against protein targets within higher-order eukaryotic cells, 
such as those of a predatory species, are of great interest for drug discovery. The differences 
in biochemical processes between multicellular aquatic organisms like sponges and corals, 
microbes and terrestrial mammals represents an attractive niche for bioprospecting within 
marine environments, often leading to the discovery of compounds with useful therapeutic 
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properties. These protein targets are often critical to the maintenance of regular cellular 
processes, thus the ability to disrupt normal biological activities in a predator is beneficial 
for both microbiota and the host-organism (Thakur and Müller 2004). Similarly, adaption 
of these compounds to interfere with an aberrant cellular process in a human diseases 
presents a convenient opportunity for exploitation for medicinal purposes. The ability to 
modulate mammalian biochemical pathways with small molecules has led to the 
development of many novel bioactive compounds in pharmaceutical applications (Buss and 
Butler 2004). Clinically, natural products and their semi-synthetic derivatives make up a 
large portion of front line therapeutic agents in the treatment of cancers (Newman and 
Cragg 2012), with many of the compounds interacting directly with targets in the 
cytoskeletal elements of eukaryotic cells. Compounds exhibiting bioactivity against critical 
protein targets, such as actin or tubulin, are of particular interest in the development of 
novel therapeutic agents. Secondary metabolites with these properties serve as an excellent 
structural scaffold for the design of variant analogues, tuned through synthetic chemistry 
to augment the initial bioactive properties of nature’s template molecules. Modifications 
are made through a rational approach based on evidence provided by structure-activity 
relationship studies (SARs), leading to the eventual development of compounds with an 
enhanced therapeutic window. A combination of modern crystallographic techniques, 
chemoinformatics, ligand-based drug design and in silico computational approaches are 
continually improving our ability to identify highly-specific candidate molecules (Seddon, 
Lounnas et al. 2012). 
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1.1.2 Cancer and therapeutic opportunities 
Cancers, as a collection of diseases, are becoming more prevalent in modern society. One 
in four deaths in the USA are cancer related; however, the survival rate of patients with 
various cancers is improving, as indicated by a consistent decrease in the incidence of 
deaths per year caused by cancers in recent decades (Siegel, Naishadham et al. 2012). This 
is likely the result of improved awareness surrounding these diseases leading to earlier 
medical intervention rather than drastic improvements in treatment. Incremental advances 
in the way our medical systems approach these diseases have contributed to better 
therapeutic outcomes; however, relevant screening programmes are not available to 
everyone, and many cancers are only detected in the advanced stages of disease progression 
(World Health Organisation, WHO, 2014).  The incidence of disease frequency is 
comparable worldwide, positioning cancers as a leading cause of death globally (Jemal, 
Bray et al. 2011) alongside cardiovascular complications, particularly in westernised 
countries (WHO). The New Zealand population follows similar trends, with 8,891 cancer 
related deaths from a total of 20,050 registered diagnoses in 2011 (NZ Ministry of Health, 
2014). Cancers are characterised as diseases in which a subset of cells exist in a state of 
hyper-proliferative, unregulated growth as the result of accumulated mutations. These 
mutations may occur in a wide array of genetic elements; however, mutations are most 
commonly associated with sequence encoding proteins involved in cellular proliferation, 
differentiation and mitogenesis, mechanisms of DNA repair or the regulation of cell death 
(Hanahan and Weinberg 2000, Futreal, Coin et al. 2004, Stratton, Campbell et al. 2009). 
Both the severity and prevalence of these diseases in society is a major driver for drug 
discovery and development in the pursuit of continually improved therapeutic outcomes. 
Traditionally, the treatment of many solid tumours has been limited to surgical resection. 
This approach, however, has deficiencies in its ability to remove all affected tissue, often 
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leading to an eventual recurrence in tumour growth. Surgical methods are limited to solid-
type tumours, with an additional difficulty in tissue removal from delicate organs such as 
in neoplasms of the brain, where critical functions may be severely impaired following 
resection (Black and Ronner 1987, Asthagiri, Pouratian et al. 2007). In the clinic, options 
are often limited to radiotherapy and chemotherapeutic approaches as our best treatments 
for cancers following the partial resection of any accessible tissue, especially in inoperable 
tissues or those with contiguous secondary lesions (DeAngelis 2001, Stupp, Mason et al. 
2005). Cancers developing metastatic properties or those originating in the progenitor cells 
of circulatory systems, for example leukemic disease forms, escape surgical methods 
entirely due to delocalisation of cells with altered surface adhesion or chemokine response 
properties (Müller, Homey et al. 2001, Hood and Cheresh 2002, Kaplan, Riba et al. 2005, 
Bos, Zhang et al. 2009).  
Most chemotherapeutic agents in clinical application for the treatment of cancers act on 
mechanisms involved in DNA replication or by targeting specific processes within cell 
division. Recent advances in genomics look promising for matching specific cancer 
genotypes to the most appropriate therapeutic agents (Al-Lazikani, Banerji et al. 2012); 
however, the need to continually improve on existing compounds or discover novel 
mechanistic targets remains prevalent for the development of effective future treatments. 
Chemotherapeutic approaches are cytotoxic in nature, and exhibit significant off-target 
effects as seen in yeast chemical-genetic screens (Kaelin 2005). This somewhat limits their 
efficacy in a therapeutic context. The majority of chemotherapeutic agents lack selectivity 
against cancerous cells and act instead as blunt, broad-spectrum cytotoxins against all 
rapidly dividing cells. This includes many healthy cell types within systemic tissue, leading 
to the aggressive side effects seen in patients undergoing chemotherapeutic regimes. 
Various proteomic and chemical-genetic approaches seek to understand these off-target 
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effects in the hope of developing new, highly specific compounds with more tolerable side 
effect profiles (Evans and McLeod 2003).  
1.1.3 Microtubules as targets in chemotherapeutic approaches to cancer treatment 
Subcellular organisation within eukaryotic organisms is highly regulated by a number of 
structural proteins, which together make up the cytoskeleton. These proteins function as a 
unified system to maintain processes within the cell including cell division, intracellular 
transport, cell macrostructure and motility. Cytoskeletal elements contribute a major role 
in cell division by both meiosis and mitosis, with roles in organelle segregation, 
chromosomal separation and cytokinesis (Hayden, Bowser et al. 1990, Field, Li et al. 1999, 
Nogales 2000, Wittmann, Hyman et al. 2001). Microtubules are heterodimeric macro-
polymers consisting of relatively small (100 kDa) α/β-tubulin dimers (Nogales, Whittaker 
et al. 1999, Kavallaris 2010). These structures are key components of the cytoskeletal 
system, making them attractive targets for the disruption of hyper-proliferative cells in the 
treatment of cancers (Jordan and Wilson 2004). Both the α- and β- tubulin monomers 
consist of three functional peptide domains – an N-terminus nucleotide-binding motif, a C-
terminus region consisting of helical structural elements, and a smaller central domain of 
looped peptide structure involved in the formation of the microtubule lumen (Nogales, 
Whittaker et al. 1999). Each of these domains have specialized roles within the microtubule 
polymer. The central domain is comprised of primarily β-sheet secondary structure and 
contributes to favourable α- to β- subunit associations (Nogales 2000). Within the N-
terminal peptide region, a critical GTP binding motif acts as a catalytic site for regulating 
polymerisation behaviours (Nogales 2000). The C-terminal structural region contributes 
peptide structures involved in favourable binding of microtubule-associated proteins 
(MAPs) (Miyamoto, Perlman et al. 2003, Amos and Schlieper 2005).  The formation of 
α/β-tubulin heterodimers is a highly controlled process, mediated through interactions with 
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multiple chaperone proteins and associated co-factors within the cytosol (Lewis, Tian et al. 
1996, Tian, Huang et al. 1996, Liang and MacRae 1997).Tubulin heterodimers are formed 
by a polar interaction of each subunit in a head to tail addition, leading to the development 
of an extended linear structure known as the protofilament. Multiple protofilaments interact 
through a lateral association of individual heterodimer units within the filament, with a 
structural element known as the M-loop assisting in stabilising the major interdimer 
associations (Nogales, Whittaker et al. 1999). Cryo-electron microscopy (CEM) studies in 
both cell extracts and purified tubulin from Xenopus eggs has revealed polymorphisms in 
the number of protofilaments making up complete microtubule polymers; however, under 
physiological conditions the large majority of polymers consist of 13 associated 
protofilaments (Chrétien, Metoz et al. 1992). Microtubule assembly in vitro is altered in 
the presence of microtubule-targeting agents (MTAs), leading to polymers with varied 
protofilament stoichiometry (Andreu, Bordas et al. 1992, Matesanz, Rodriguez-Salarichs 
et al. 2011). The complete microtubule polymer is approximately 24 nm in diameter and 
surrounds a hollow, luminal space (Nogales, Whittaker et al. 1999). 
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Nomenclature for describing tubulin macrostructure has been developed over time, based 
around conserved secondary structural features within folded tubulin-family peptide 
sequence. Residues 1- 206 are defined as the N-terminal region, residues 207- 384 the 
central domain followed by 385 – 415 as the C-terminal structural region. Each major 
alpha-helix or beta-sheet structure is defined numerically in sequence from the amino-
terminal of the peptide sequence as in figure 3 of Lowe, Li et al. (2001). This thesis utilises 
this nomenclature for any further reference to specific amino acid residues as below in 
figure 1.1.1.  
 
 
 
 
Figure 1.1.1 Linearized peptide sequence of β-tubulin. Sequence colour denotes structural elements. 
Sequence in pink indicates α-helices, blue for β-sheets and looped sequence is represented in yellow. 
The M-loop, a region critical to interdimer stabilisations is shown in purple. Residues 1-206 
constitute the N-terminal domain, the central domain indicated by residues 207-384 followed by the 
C-terminal domain. Sequence elements are denoted according their corresponding structural role - S 
= Sheet, H = Helices. Nomenclature is assigned as published in (Lowe, Li et al. 2001) PDB JFF1. 
Figure taken with author’s permission from Field, Díaz et al. (2013). 
 
8 
 
Microtubules were first identified in the early 1960’s during the development of electron 
microscopy (EM) (Ledbetter and Porter 1963, Slautterback 1963). Soon after, microtubule 
subunits were isolated as the primary binding target of colchicine (Borisy and Taylor 1967, 
Weisenberg, Borisy et al. 1968), a compound with anti-mitotic properties now thoroughly 
characterised as a potent MTA. Through these early discoveries, chemical entities with 
binding affinity to microtubule proteins were quickly realised as valuable therapeutic 
agents for their powerful effects on disrupting normal cellular processes. Tubulin family 
proteins are among the most abundant protein species within all eukaryotic cells, with 
isoform distributions highly dependent on tissue specific regulatory processes (Sullivan 
1988). Both the abundance of these proteins, their critical biological role and the newfound 
ability to perturb their function with specific compounds lead to the rapid development of 
first generation chemotherapeutic agents for the treatment of cancers. 
  
Figure 1.1.2 Microtubule polymer-assembly. Individual tubulin monomers associate to form tubulin 
heterodimers (A). Heterodimers associate in a head to tail arrangement, forming linearized 
protofilament structures (B). Lateral associations between monomers within individual 
protofilaments (C) leads to the generation of complete microtubule polymers (D). These generally 
consist of thirteen protofilaments in vivo. Figure adapted from Jordan and Wilson (2004) with 
publisher’s permission. 
C D B A 
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1.1.4 Introduction to human tubulin genes 
Tubulin proteins are the products of a highly conserved gene family with ubiquitous 
presence across all eukaryotic genomes. On an evolutionary timescale, the critical nature 
of these proteins in the eukaryotic cytoskeleton has led to the development of multiple 
unique tubulin gene variants, each encoding tubulin proteins with highly specialised 
functional roles that differ between organisms, tissue types and even temporally within a 
single cell (Dumontet, Durán et al. 1996, Erickson 2007, Wickstead and Gull 2011). The 
gene family consists of α-, β-, γ-, δ-, ε-, ζ- and η-tublins (Dutcher 2001), alongside 
structurally similar prokaryotic gene variants encoding FtsZ – A tubulin-related GTPase 
(Erickson 1995, Du Toit 2014). In humans, the α- and β- tubulin protein species make up 
the majority of cellular tubulin content necessary for cytoskeletal microtubules. Within 
these species, tissue-specific isotype expression results in a range of tubulins with varied 
biochemical properties dependent on unique peptide sequence, post-translational 
modifications or global protein stability (Ludueña 1993, Verdier-Pinard, Pasquier et al. 
2009). Among the β-tubulins, βI-tubulin is most widely distributed among various tissues, 
and many studies have shown MTA resistant cells develop altered isotype expression 
profiles, particularly in upregulation of βIII-tubulin (Kavallaris 2010). This phenomenon is 
seen similarly in cells resistant to Pel A and Lau (Kanakkanthara, Wilmes et al. 2011). As 
the primary β-tubulin isotype of the cell lines used in this study, the human βI-tubulin gene 
was selected for the introduction of the D297I point mutation. 
 
1.1.5 Microtubule-Dynamics 
 Microtubule-targeting agents have a history of relative success as cancer 
chemotherapeutics (Jordan and Wilson 2004), predominantly attributed to their potent 
effect on disrupting critical reorganisations of nuclear material, preventing cell cycle 
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progression into the mitotic phase. Microtubules are highly dynamic in nature, 
demonstrating rapid rearrangements of tubulin heterodimers during periods of polymer 
extension or shortening. This behaviour, termed dynamic instability, describes fluctuations 
in heterodimer movement within the polymer macrostructure in response to changes in 
cellular requirements (Mitchison and Kirschner 1984, Nogales 2000). 
 
The GTP binding motif of the N-terminal region in β-tubulin, termed the E-site, acts as a 
catalytic exchange site for modulating microtubule polymerisation behaviours. The 
exposed β-tubulin end, or plus end (+), of the microtubule is where a large portion of 
dynamic activity takes place (Akhmanova and Steinmetz 2008). The E-site of tubulin 
modulates the strength of lateral protofilament associations by a GTP/GDP induced 
allosteric shift between either a straight or curved conformation within the tubulin subunit 
(Nogales, Wang et al. 2003). When bound to the E-site, GTP induces a straightened 
conformation in tubulin, promoting a more favourable lateral interaction with tubulins in 
adjacent protofilaments. Bound GTP is then rapidly hydrolysed to GDP, introducing an 
energetic strain as β-tubulin shifts to re-adopt the curved conformation (Nogales, Wang et 
al. 2003). The rapid addition of a further GTP-bound tubulin heterodimer somewhat 
stabilises this strain, and allows lateral associations within the microtubule lattice to be 
maintained. The presence of GTP in the E-site of β-tubulins shifts dynamic equilibrium in 
favour of microtubule polymerisation, leading to overall elongations in polymer 
macrostructures. GTP associated with the (+) end of the microtubule serves to prevent 
depolymerisation of the microtubule and is consequently referred to as the GTP cap 
(Akhmanova and Steinmetz 2008). 
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Figure 1.1.3 Microtubule dynamics and macropolymer structure. α- and β-tubulin monomers 
associate to form heterodimers. These then bind to GTP co-factors through the nucleotide binding 
motif in the N-terminal region of β-tubulin (pink). Polymerisation is favoured when GTP bound 
heterodimers are available in the cytosol, with rapid heterodimer addition to the microtubule 
polymer (1). GTP hydrolysis occurs soon after heterodimer addition, favouring depolymerisation 
as GDP-associated heterodimers (purple) return to a curved conformation. The addition of further 
GTP-associated heterodimers prevents this depolymerisation, thus a stabilised (2) or growing 
microtubule exhibits a characteristic GTP ‘cap’. In the absence of GTP-associated heterodimers, 
the curved conformation of tubulin results in protofilaments appearing to ‘peel’ away from the 
lattice, resulting in microtubule depolymerisation (3). A shift in dynamics favouring polymerisation 
is known as ‘rescue’ while microtubule ‘catastrophe’ describes a shift towards depolymerisation of 
microtubule polymers. Figure adapted from (Akhmanova and Steinmetz 2008) with publisher’s 
permission. 
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In contrast, the lasting presence of GDP in the E-site of β-tubulin or the loss of the GTP 
cap favours disassembly of tubulin heterodimers. The curved conformation of GDP-
associated-tubulin has low stability within the microtubule lattice in the absence of a GTP 
cap. Energetic strain within the lattice is relaxed as protofilaments peel away, leading to an 
overall reduction in total polymer length (Caplow, Ruhlen et al. 1994). This may occur as 
the result of reduced cytosolic GTP availability or when rates of GTP hydrolysis exceed 
GTP binding to the E-site (Janosi, Chretien et al. 2002). The N-terminal nucleotide binding 
motif of α-tubulin, termed the N-site, is non-exchangeable and may only be occupied by 
GTP. This results in lesser dynamic activity at the α-tubulin subunits of heterodimers that 
are exposed in the minus (-) end of the microtubule. The presence of GTP exclusively in 
the N-site promotes higher stability in the lateral associations with adjacent α-tubulins 
(Nogales, Whittaker et al. 1999, Akhmanova and Steinmetz 2008). A transition from the 
growth state to one of depolymerisation is termed microtubule ‘catastrophe’ while 
reinstatement of lowered GTP hydrolysis rates and the associated shift towards microtubule 
polymerisation is known as microtubule ‘rescue’(Jordan and Wilson 2004). Together, these 
processes allow global regulation of microtubule growth states as required for the 
maintenance or initiation of critical cellular processes. 
Microtubules exhibit a second major behaviour whereby dynamic equilibrium is 
homeostatic and polymers exhibit no significant change in overall length. This is known as 
microtubule treadmilling, a flux process delicately regulated by GTP hydrolysis and tubulin 
isotype-specific binding stabilities that results in an equal rate of heterodimer gain from the 
(+) end of the microtubule as they are lost at the (-) end (Nogales 2000). Upon transition 
from the interphase to mitotic phase of cell division in somatic cells, the degree of dynamic-
instability seen in microtubules increases significantly as polymers rearrange to form 
structural elements such as the mitotic spindle (Rusan, Fagerstrom et al. 2001). 
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1.1.6 Microtubule targeting agents 
MTAs interfere with microtubules dynamics through a number of mechanisms, preventing 
critical rearrangements in cytoskeletal elements and severely hindering many biological 
processes within the cell (Jordan and Wilson 2004). The cytotoxic effect of MTAs has been 
largely attributed to their effects on cell cycle progression. By disrupting the dynamic 
behaviour of microtubules, cells undergo mitotic arrest, leading to an induced cell death 
response through the intrinsic pathways of apoptosis (Jordan, Wendell et al. 1996). This is 
most readily seen in cells attempting to rearrange microtubules in order to form elements 
of the mitotic spindle and asters during cell division; actions that are severely inhibited in 
the presence of MTAs (Kelling, Sullivan et al. 2003). The ability to hinder these processes 
in a rapidly dividing cell population, such as in cancer, make MTAs ideal candidate 
molecules for use in the clinic. The relative success of many MTAs is attributed to this 
ability to induce mitotic arrest; however, mitosis-specific inhibitors such as those targeting 
specific mitotic kinases such as the Polo and Aurora kinases (reviewed in Taylor and Peters 
(2008)) have seen little clinical success (Komlodi-Pasztor, Sackett et al. 2012). This 
suggests that MTAs may in fact exert many of their potent in vivo cytotoxic effects by 
inhibiting microtubule dynamics during the interphase of the cell cycle, hindering processes 
of normal intracellular trafficking (Komlodi-Pasztor, Sackett et al. 2011, Komlodi-Pasztor, 
Sackett et al. 2012, Field, Kanakkanthara et al. 2014). New targeted therapeutics are 
beginning to emerge utilising antibody-MTA conjugates to introduce microtubule 
disruption within specific cell populations (Panowski, Bhakta et al. 2014) by targeting 
novel biomarkers of even the most difficult cancers (Pointer, Clark et al. 2014). These new 
generation therapeutics are beginning to enter the clinic (Younes, Yasothan et al. 2012), 
Ballantyne and Dhillon (2013), (Dhillon 2014) and show positive results. MTA compounds, 
however, remain essential for the mechanism through which these antibody-targeting 
therapeutics exert their toxicity. 
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The vast majority of compounds characterised as MTAs have origins in natural products, 
with many then altered through synthetic chemistry for enhanced therapeutic properties. 
MTAs inhibit microtubule dynamics through two broadly defined mechanisms, leading to 
a categorisation as either a microtubule-destabilising agent (MDA) or microtubule-
stabilising agent (MSA). At low concentrations in vitro, both classes of compound appear 
to disrupt normal dynamic behaviour in microtubules, leading to mitotic arrest and 
apoptosis. At higher concentrations, each class of compound begins to produce 
characteristic behaviours in the dynamic instability of tubulin heterodimers. MDAs  begin 
to reduce polymer length significantly, and may eventually deplete microtubule structures 
entirely (Jordan and Wilson 2004). MSAs in contrast, are able to stabilise heterodimer 
polymerisation at high concentrations. These agents induce polymerisation of heterodimers 
in the absence of GTP, or even those with exclusively N-site associated GDP. This leads to 
an in increase in polymer mass, the formation of microtubule bundles and a characteristic 
formation of multiple asters or aberrant centrosomes. The action of MTAs is determined 
by how each compound interacts within the tertiary structure of the α/β-tubulin polymer. 
MTAs have a unique binding interaction with one of four distinct regions on β-tubulin 
(Huzil, Chik et al. 2008, Dumontet and Jordan 2010). Changes in microtubule dynamics as 
a result of drug treatment are dependent on the particular binding-region with which a 
compound associates. 
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1.1.7 Microtubule destabilising agents 
Many compounds demonstrate an ability to bind microtubules, inhibit polymerisation 
dynamics or even reverse assembly altogether. These MDAs associate with one of two 
regions on β-tubulin with names based on the first described compounds showing specific 
binding affinity to these regions. Colchicine-like compounds and vinca domain-binding 
agents describe two classes of compound with respective binding affinities either for the 
colchicine or vinca domains of β-tubulin. Each of these binding regions is located on the 
exterior region of the microtubule polymer wall.  
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Colchicine domain binding agents 
Colchicine-like compounds bind soluble heterodimers and effectively ‘lock’ the tubulin 
into a curved conformation. This decreases the stability of heterodimer integration into the 
microtubule lattice (Ravelli, Gigant et al. 2004), leading to depolymerisation, especially at 
higher concentrations. Despite the early identification of colchicine as a MDA as described 
in section 1.1.3, colchicine-like agents have yet to progress through clinical trials 
(Dumontet and Jordan 2010, Massarotti, Coluccia et al. 2012). Structural analogues that 
bind the colchicine site are, however, showing promise for treating cancers with selective 
vascular disruptions and are moving through late stage trials (Dumontet and Jordan 2010, 
Larocque, Ovadje et al. 2014).  
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Figure 1.1.4 The colchicine binding region. Colchicine associated compounds bind a region on 
the external microtubule wall, as indicated by the purple square. A selection of chemical structures 
of compounds known to associate with the colchicine binding domain of β-tubulin are also 
presented. Figure adapted from Dumontet and Jordan (2010) with publisher’s permission. 
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Vinca domain binding agents 
Vinca domain binding agents such as vinblastine (approved 1961) and vincristine 
(approved 1963) have seen much success as MDAs in cancer therapies (Yue, Liu et al. 
2010). Many structural analogues have since been developed and moved through for 
clinical use against a diverse range of cancers (Dumontet and Jordan 2010). Vinca domain 
binding agents associate directly with β-tubulin in the polymerised microtubule structure 
(Cormier, Knossow et al. 2010) and introduce disruptions in microtubule dynamics. It is 
thought that these compounds are able to interfere with regulation functions at the 
organisational centres of  the (-) end of the microtubule, causing polymer fragmentation 
leading to inhibition of cell cycle progression (Yang, Ganguly et al. 2010). Despite their 
success, many vinca domain binding agents are susceptible to drug efflux pumps in cancer 
cells with MDR phenotypes; therefore, the development of analogues with improved 
properties is ongoing (Dumontet and Jordan 2010). 
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Figure 1.1.5 The vinca domain binding region. Vinca domain associated compounds bind a region 
on the external microtubule wall as indicated by the orange triangle. A selection of chemical 
structures of vinca domain binding compounds are also presented. Figure adapted from Dumontet 
and Jordan (2010) with publisher’s permission. 
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1.1.8 Microtubule-stabilising agents 
The second major class of MTAs able to disrupt microtubule dynamics do so by stabilising 
interactions between tubulin heterodimers within the microtubule polymer (Dumontet and 
Jordan 2010). MSAs interfere with regular processes of dynamic instability by interacting 
with one of two distinct binding regions on β-tubulin. The majority compounds identified 
as MSAs interact with the well characterised taxane binding region, while two novel marine 
natural products, peloruside A (Pel A) and laulimalide (LAU) display unique activities at a 
secondary site that has only recently been described (Huzil, Chik et al. 2008, Nguyen, Xu 
et al. 2010). 
Taxanes 
Taxane compounds represent the earliest known microtubule-stabilisers, with paclitaxel 
(PTX) first reported as demonstrating microtubule-stabilising properties in 1979 (Schiff, 
Fant et al. 1979), shortly after the compound was identified and shown to have potent 
antimitotic properties (Wani, Taylor et al. 1971). The compound was first isolated from the 
Pacific yew tree Taxus brevifolia in 1966. The potential anticancer activity of this 
compound was quickly realised, however its further development was limited by scarcity 
in the supply from raw biomass. Soon after, plant tissue culture methods were developed 
to produce an abundant precursor, 10-deacetyl-baccatin III, allowing semi-synthetic PTX 
to be produced for research and medical applications (Witherup, Look et al. 1990, Rohena 
and Mooberry 2014).  PTX and its many derivatives stabilise microtubule polymers by 
binding to the taxane site of β-tubulin, located in the luminal space of the microtubule. 
These compounds associate with GDP-bound β-tubulin, relieving curvature in the protein’s 
tertiary conformation, thus reinstating the favourable inter-protofilament interactions of the 
straightened tubulin form, and leading to increased polymer mass within a cell. (Elie-Caille, 
Severin et al. 2007). PTX has been in clinical application since 1992 as an antimitotic for 
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treating a range of cancers, including those of breast, ovarian or lung tissues (Yue, Liu et 
al. 2010). PTX and its derivatives have undergone many iterations, improving on limiting 
pharmacological properties such as the compound’s low aqueous solubility and need for a 
lipophilic delivery vehicle (such as Cremophor EL) (Gelderblom, Verweij et al. 2001)  and 
susceptibility as a substrate for Pgp pump activity, especially in cells with MDR 
overexpression phenotypes (Gaitanos, Buey et al. 2004). There are a number of paclitaxel 
analogues in clinical application or late stage clinical trials, including those exploring 
advanced formulations or drug-nanoparticle-biomolecule conjugates (Rohena and 
Mooberry 2014).
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Figure 1.1.6 The taxane binding region. A selection of compounds with affinities to the taxane 
binding domain are also presented. These compounds associate to a region within the microtubule 
lumen as indicated by the yellow diamonds. Compounds have incredibly diverse chemical structure 
and come from plant, microbial and marine derived sources.  Figure adapted from Dumontet and 
Jordan (2010) with publishers permission. 
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Epothilones 
Epothilones are a class of chemical agents originally isolated from the microbial species 
Sporangium cellulosum (Gerth, Bedorf et al. 1996). Epothilones A and B, the two major 
isolated products, demonstrated potent microtubule-stabilisation activities. This made them 
the first novel group of MSAs discovered since PTX (Bollag, McQueney et al. 1995). These 
compounds were of significant clinical interest as their potency was comparable to PTX 
and its derivatives, yet activity was retained in Pgp-over expressing MDR resistant cell 
lines. Epothilone B (azaepothilone B) is in fact a substrate for Pgp efflux; however, it is not 
a substrate for the breast cancer resistance protein BCRP/ABCG2 (Shen, Lee et al. 2011). 
The mechanism by which these compounds induce microtubule-stabilisation is similar to 
PTX, with binding affinity in the taxoid region of β-tubulin (Prota, Bargsten et al. 2013). 
Epothilones are readily produced through bioreactor fermentation, or a relatively simple 
synthetic route given the 16-membered macrolide structure exhibits less complexity than 
other natural products (Rohena and Mooberry 2014). A derivative of epothilone B, 
azaepothilone B, has been in clinical applications for the treatment of refractory metastatic 
breast cancers since 2007 under the trade name Ixempra® (Bristol-Myers Squibb). 
Taccalonolides  
Taccalonolides are a class of compounds only recently described as having MSA activity. 
Taccalonolides A and E were found to induce characteristic microtubule polymerisation in 
treated cells; however, direct interactions with tubulin were not detected in these early 
studies (Tinley, Randall-Hlubek et al. 2003, Rohena and Mooberry 2014).These 
compounds are poor substrates for Pgp efflux pumps and retain activity in cell lines with 
mutations in the taxane binding region of β-tubulin and cell lines with varied β-tubulin 
isotype compositions (Peng, Risinger et al. 2011, Risinger, Westbrook et al. 2011). 
Investigations into the taccalonolide analogues taccalonolide AF and synthetic 
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taccalonolide AJ have shown the ability to induce polymerisation of purified tubulin in 
vitro; however, the mechanisms by which this occurs appear somewhat dissimilar to PTX 
(Li, Risinger et al. 2011, Risinger, Westbrook et al. 2011). More recently, covalent 
interactions with β-tubulin in the taxane binding region have been identified and the 
unusual properties of these compounds are beginning to be better understood (Li, Risinger 
et al. 2014). Understanding the mechanisms by which these compounds induce 
microtubule-stabilisation may be incredibly valuable to the development of therapeutic 
MSAs in the future. 
 
1.1.9 Microtubule-stabilising agents of marine origin 
Marine organisms have to date been the most abundant source of novel microtubule-
stabilising agents (Rohena and Mooberry 2014). Compounds including the 
discodermolides, dictyostatins, zampanolides, dactylolides, eleutherobins, and 
sarcodictyins have all demonstrated the ability to induce microtubule-stabilisation through 
various mechanisms by interacting with the taxane binding region on β-tubulin (Field, Díaz 
et al. , Rohena and Mooberry 2014) favouring a straightening in tubulin conformations or 
improving protein-protein interactions via stabilisation of the M-loop region in tubulin 
(Prota, Bargsten et al. 2013). Interestingly, cyclostreptin (Buey, Calvo et al. 2007), 
zampanolide and dactylolide (Field, Pera et al. 2012, Larsen, Wilson et al. 2013), undergo 
unique covalent binding within the taxane region of β-tubulin, a novel pharmacological 
property that may be of future clinical value. Clinical development of most of these 
compounds has been slow given the complex chemical-syntheses involved in producing 
the compounds or their difficulty of isolation from natural sources. Two additional marine 
natural products, peloruside A (Pel A) and laulimalide (Lau) are the focus compounds of 
this study, and are covered in more detail in the following sections. 
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Thus far, all natural products with MSA activity in clinical applications share a mechanistic 
region of action in the taxane site of β-tubulin. Two novel macrolides, Lau and Pel A act 
as potent microtubule-stabilising agents in vitro and produce similar disruptions in the 
dynamic-instability of tubulin as seen with traditional MSAs like PTX. These compounds, 
and their synthetic derivatives, have seen great interest in recent years following the initial 
characterisation of their novel binding region within β-tubulin. 
  
αTub  βTub 
Figure 1.1.7 Chemical structures of two novel marine natural products LAU and Pel A. Both 
compounds are complex polyketides and demonstrate a potent ability to induce microtubule 
stabilisation in vitro. These compounds share a unique binding region within the β-tubulin monomer, 
localised in close proximity to the M-loop. 3D representations of the α/β-tubulin heterodimer are 
presented, with both Lau (left) and Pel A (right) co-localised to the predicted binding region of β-
tubulin. Pel A and Lau occupy a distinct region from that of PTX (right) Figures adapted from 
(Nguyen, Xu et al. 2010, Prota, Bargsten et al. 2014) with authors’ permission. 
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Lau, a 20-membered macrolide first isolated from the marine sponges Hyattella sp. and 
Cacospongia mycofijiensis in 1988 (Corley, Herb et al. 1988, Quinoa, Kakou et al. 1988). 
Initial characterisations found Lau to act as a potent MSA with nanomolar range bioactivity 
in vitro (Mooberry, Tien et al. 1999). Early binding studies revealed Lau did not inhibit the 
binding associations of radiolabeled or fluorescent paclitaxel derivatives (Pryor, O'Brate et 
al. 2002), suggesting an alternate mechanism was involved in Lau-induced microtubule 
polymerisation. In addition, Lau was found to retain activity in cell lines with mutations in 
the taxane binding region which conferred resistance to epothilone A, epothilone B and 
PTX (Pryor, O'Brate et al. 2002) and those with Pgp overexpression and MDR phenotypes 
(Liu, Towle et al. 2007). Lau has been assessed in various tumour models; however, the 
compound has demonstrated mixed ability to inhibit tumour growth in vivo (Johnson, 
Tenney et al. 2007, Liu, Towle et al. 2007). This may be in part due to the relatively high 
lipophilicity of Lau (Mooberry, Tien et al. 1999), resulting in poor bioavailability of the 
compound in target tissues. 
Pel A, a 16-membered macrolide first isolated from the New Zealand marine sponge 
Mycale sp. (West, Northcote et al. 2000) and was soon after characterised as a potent 
cytotoxin (Hood, Bäckström et al. 2001). The compound’s mode of action for inducing cell 
death was identified through its characteristic MSA-like activity in vitro (Hood, West et al. 
2002). Surprisingly, competition studies revealed Pel A shared a binding region with Lau, 
but not PTX (Gaitanos, Buey et al. 2004) and, like Lau, was a poor substrate for Pgp drug 
efflux mechanisms. This makes Pel A and its structural analogues of significant clinical 
interest as potential chemotherapeutics for use in cases of cancer with mutations in amino 
acids located within the taxane-binding region or those with MDR phenotypes against 
traditional MTAs. Studies into the synergistic capabilities of Pel A with taxane-region 
targeted compounds have indicated that combination therapy approaches utilising the novel 
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binding region of compounds like Pel A or Lau along with the traditional taxoid site 
compounds may be a beneficial strategy in future chemotherapeutic regimes (Hamel, Day 
et al. 2006, Wilmes, Bargh et al. 2007, Kanakkanthara, Wilmes et al. 2011). 
Both Pel A and Lau serve as excellent structural scaffolds for the development of next-
generation antimitotic agents. These compounds act by a similar mechanism to the frontline 
chemotherapeutic agent PTX, yet exhibit novel pharmacological properties and maintain 
activity in drug resistant tissue types. In order to fully utilise these structures through 
adaptive synthetic-chemistry, complete characterisation of the novel binding region with 
which they engage is essential. Recently, a combination of hydrogen-deuterium exchange 
mass spectrometry (HDX-MS) (Huzil et al. 2008; Khrapunovich-Baine et al. 2011), 
mutational analysis of individual tubulin amino acid residues (Kanakkanthara et al. 2014), 
and x-ray crystallographic techniques (Prota, Bargsten et al. 2014) has begun to extend our 
knowledge of the critical drug-protein interactions through which both Lau and Pel A are 
able to stabilise tubulin polymerisation. By understanding these interactions, the potency 
and specificity of Pel A and Lau will be improved by alterations in chemical structure to 
improve on the clinical potential of these compounds. To progress these compounds toward 
clinical application, biological verification of the predicted drug-amino acid interactions 
within the Pel A/Lau binding region in these models is an essential insight useful for the 
rational development of synthetic Pel A/Lau analogues with improved therapeutic windows.  
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1.2.0 Research design 
The Pel A/Lau binding region of tubulin has received considerable interest in recent years 
given the potential this region represents for the development of novel chemotherapeutic 
agents. Traditionally, electron crystallography by CEM or x-ray diffraction techniques have 
been utilised to study microtubule structure or tubulin-ligand associations as in the case of 
solving the PTX-tubulin interaction (Lowe, Li et al. 2001). These approaches utilise a Zn2+ 
surface to stabilise the formation of 2-D tubulin crystal sheets in order to generate 
diffraction data. Unlike PTX, Lau does not produce a 2-D crystalline tubulin sheet on Zn2+ 
(Thepchatri, Cicero et al. 2005). This prevented elucidation of the structure by x-ray 
crystallography, thus early insights into the Pel A/Lau binding region on β-tubulin relied 
on alternate methodologies. Huzil, Chik et al. (2008) utilised HDX-MS peptide mapping 
techniques to avoid the problematic aspects of generating Zn2+ crystal sheets in initial 
investigations into the binding modality of Pel A, generating evidence in support of a novel 
region within β-tubulin that may be a useful target for the stabilisation of microtubules. 
These studies were followed by refined models of Pel A/Lau binding within the proposed 
region, generated by computational methods, mass shift perturbation and radiolabeled [3H]-
Pel A affinity techniques (Bennett, Barakat et al. , Nguyen, Xu et al. 2010); however, each 
group offered an alternate prediction of  Pel A orientation within the binding region. Further 
HDX-MS data generated by Khrapunovich-Baine, Menon et al. (2011) supported the initial 
binding region proposed by Huzil, Chik et al. (2008) as this region was highly protected 
from deuterium incorporation by both Pel A and Lau, and suggested these compounds 
strongly enhance interprotofilament association between β-tubulins through an induced 
stabilisation of the M-loop structural region (Khrapunovich-Baine, Menon et al. 2011). 
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More recently, Prota, Bargsten et al. (2014) unified aspects of these proposed models 
through elucidation of the tubulin ternary crystal structure while in complex with each of 
Pel A, Lau and Epothilone A. This was achieved through the crystallisation of α/β tublin in 
complex with the stathmin-like protein (SLD) RB3, and tubulin tyrosine ligase (TTL) 
(Prota, Bargsten et al. 2013, Prota, Magiera et al. 2013). Crystals suitable for study by x-
ray diffraction were produced through the use of this complex, thus avoiding obstacles 
associated with Zn2+ tubulin crystal sheets. These studies provided an in depth model for 
compound modality within the novel Pel A/Lau binding region of β-tubulin, and has 
allowed further predictions to be made regarding the functional role of individual amino 
acid-drug associations. A mechanism through which Pel A or Lau may induce microtubule-
stabilisation has been proposed alongside these predictions – A critical development in our 
understanding of this novel MSA-target site in β-tubulin. In addition, Churchill, 
Klobukowski et al. (2014) have recently modelled the binding association of β-tubulin with 
Lau in the presence of an adjacent protofilament, observing  a large number of H2O 
mediated bonding interactions in the consensus region. With interactions from Lau bridging 
the interdimer space, residues E53, K122, E125, S126 and D128 on the adjacent β-tubulin 
were identified as contributors in the binding association.  
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The research presented within this thesis aims to explore the role of aspartic acid 297 (D297) 
located within the Pel A/Lau binding region. This amino acid has a predicted functional 
role in stabilising the binding of Pel A and Lau as first predicted by Huzil, Chik et al. (2008), 
Khrapunovich-Baine, Menon et al. (2011) and recently Prota, Bargsten et al. (2014). 
Recently Churchill, Klobukowski et al. (2014) have provided additional computational 
studies noting a contribution to ligand binding energy from this region. Initial computer 
modelling based on the Zn2+ tubulin structure suggested this particular amino acid may be 
involved in Pel A/Lau binding and was selected for this investigation before the Pel A/Lau-
β-tubulin crystal structure of Prota, Bargsten et al. (2014) was available.  In the present 
study, we seek to provide biological evidence for the role of D297 in the Pel A and Lau 
induced the stabilisation of microtubules. 
Studies in cell lines resistant to Pel A and Lau have identified distinct point mutations in 
βI-tubulin sequence that result in reduced sensitivities to both compounds. These include 
mutations in amino acids A298, R308, Y342 and N339 (Begaye, Trostel et al. 2011, 
Kanakkanthara, Eras et al. 2014). Consistent with the crystallographic predictions of Prota, 
Figure 1.1.8 The binding region of Pel A and Lau. Peloruside A is modelled within the predicted 
Pel A/Lau binding region of β-tubulin (left) alongside the α/β-tubulin-RB3-TTL complex (T2R-
TTL) used to elucidate the β-tubulin crystal structure while associated with Pel A/Lau ligands 
(right). Figure adapted from (Prota, Bargsten et al. 2014) and (Prota, Magiera et al. 2013) with 
publisher’s permission. 
T2R-TTL 
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Bargsten et al. (2014), these particular amino acids are identified as having functional roles 
in the binding association of both Pel A and Lau.  
 
Kanakkanthara, Eras et al. (2014) describe the partial resensitisation of A298 or R308 
mutant cells that are resistant to Pel A and Lau when a wild-type βI-tubulin is introduced 
by means of transient transfection. As no biological evidence is available detailing the 
many predicted drug-amino acid interactions in βI-tubulin made by Prota, Bargsten et al. 
(2014), the present study utilises a reverse approach to that used by Kanakkanthara, Eras et 
al. (2014), introducing point mutation-containing βI-tubulin subunits to the tubulin 
population in a mammalian cell line, producing a model useful for the assessment of the 
biological role that individual amino acids play in these particular drug-protein binding 
associations. By introducing mutant D297I-βI-tubulin, a subunit with an isoleucine 
substitution at position 297, transfected cultures were assessed for changes in sensitivity to 
the compounds Pel A, Lau, PTX and IXA. In addition, this research examines mutant 
protein expression in this βI-tubulin point mutation model, assessing its suitability for use 
in characterising individual amino acids in the Pel A/Lau-tubulin binding association. 
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1.3.0 Aims of this research 
The aims of the research presented in this thesis are as follows: 
1.3.1 Examine the functional role of the D297 amino acid residue of human βI-
tubulin in the predicted binding association of Pel A and Lau 
Utilising a mammalian cell line as a model for MSA-induced polymerisation dynamics, the 
D297 amino acid residue of βI-tubulin will be assessed for functional involvement in the 
βI-tubulin-Pel A or Lau binding association. By introducing a mutant βI-tubulin isoform, 
the particular involvement of D297 in Pel A/Lau drug binding will be assessed through 
observing any change in the sensitivity of a cell line in response to Pel A or Lau. The 
predicted role of D297 in the stabilisation of Pel A/Lau binding by Prota, Bargsten et al. 
(2014) suggests a point mutation at this position may disrupt favourable hydrogen bonding 
interactions between Pel A/Lau and βI-tubulin in the wild-type isoform. It is hypothesised 
that the introduction of the mutant D297I-βI-tubulin through transfection may confer 
resistance to Pel A and Lau, allowing a level of dynamic-instability to be maintained within 
microtubule polymers in the presence of either compound. This research will provide 
evidence in support of or against an interaction between D297 and Pel A and Lau. The 
extent of introduced disruption may differ between each compound, providing further 
insight into the mechanism by which each of these compounds stabilise tubulin. 
A thorough investigation into the concentration-response of wild-type, mock-transfected 
and D297I-βI tubulin-transfected cells in the presence of Pel A and Lau may reveal altered 
responses in the proliferative characteristics of transfected cultures. This will allow any 
shift in the concentration-response phenotype of D297I-βI tubulin-transfected cells to be 
considered as a direct result of the D297I mutation presence within tubulin when compared 
to the concentration-response of cells with WT βI-tubulin only. This will indicate whether 
this particular amino acid substitution is likely involved in the binding association of Pel 
33 
 
A/Lau to human βI-tubulin and provide direct biological support for or against a role of 
D297 as predicted by (Prota, Bargsten et al. 2014). 
1.3.2 Determine optimum transfection parameters for mutant βI-tubulin expression 
in a mammalian cell line 
In order to detect any changes in the sensitivity of cells transfected with a mutant βI-tubulin, 
it is hypothesised that should the D297I point mutation confer a resistance phenotype, the 
magnitude of this resistance would be dependent on the relative abundance of mutant βI-
tubulin present within the whole cell population. A mammalian cell model expressing the 
mutant βI-tubulin isoform in abundance may show a large shift in concentration-response 
should the point mutation play a functional role in the binding association of Pel A/Lau. 
This study will determine parameters for maximising mutant protein expression across the 
population for use in this model. 
The presence of mutant βI-tubulin within whole cell samples of transfected cells will be 
assessed by Western blotting to examine the abundance of mutant βI-tubulins. This will 
allow for correlation of any concentration-response changes to the presence of mutant βI-
tubulins in transfected cells treated with Pel A or Lau. 
1.3.3 Examine the integration of exogenous mutant tubulin subunits into 
polymerised microtubules 
Tubulin-family proteins play critical roles in the maintenance of normal cellular processes. 
For this reason, it was essential that the introduced mutant protein isoform was biologically 
functional and that presence of this protein does not affect the viability of transfected cells. 
Live-cell confocal microscopy will be utilised to examine the presence of the mutant βI-
tubulin subunits in situ, within polymerised microtubules. Successful integration of the 
mutant protein isoform into the tertiary microtubule structure is critical for allowing 
assessment of the D297 amino acids role in response to Pel A or Lau. 
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1.3.4 Examine the concentration-response of D297I mutant transfected cells in 
response to drugs targeting the taxane region of β-tubulin 
By assessing cells transfected with the mutant βI-tubulin against both IXA and PTX, we 
may determine whether the presence of the D297I point mutation in βI-tubulin has any 
effect on the global conformation of the protein. These drugs target a region of βI-tubulin 
situated a significant distance away from the Pel A/Lau binding region, and thus it is 
hypothesised no change in the IC50 with these compounds should be observed. If this 
hypothesis is correct, these investigations will provide further support for any change in the 
IC50 of cells with D297I-βI-tubulin in response to Pel and Lau as a result of mutation 
presence. 
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Chapter 2. Exogenous human β1-tubulins as tools for 
investigations of structural activity relationships. 
2.1 Introduction 
The material presented within chapter two of this thesis relates to experimental design and 
the generation of an experimental model for the investigation of D297 in the binding 
association of pel A and Lau.  
2.1.1 Mammalian cell models for the study of drug-protein interactions 
Mammalian cells are a valuable tool for the study of drug-target interactions, especially for 
the investigation of singular protein components within a complete cellular environment. 
Cell lines are often criticised on aspects of their physiological relevance, particularly in the 
study of complete disease states. For the purposes of this investigation, cell lines remain 
incredibly useful for generating insights into the specific binding associations of Pel A/Lau 
and tubulin as we are solely focused on drug-protein binding interactions that do not require 
a complete biological system. 
Human cells maintained in culture produce tubulin and microtubule polymers that exhibit 
normal processes of dynamic-instability. As described in chapter 1, microtubule 
polymerisation from purified tubulin heterodimers demonstrates slight alterations in 
quaternary structure from that of physiological tubulin. This makes tubulin in a cellular 
environment preferable for the study of these particular drug-protein interactions.  
Introducing genetic manipulations to produce mutant tubulin variants is slightly more 
challenging in a mammalian system when compared to other more amenable organisms 
such as the budding yeast Saccharomyces cerevisiae. This is the key reason many 
investigations into the Pel A/Lau binding region thus far have been carried out in yeasts. 
While more challenging, mammalian cells are far more sensitive to MSAs in vitro than 
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yeast, which require drug concentrations in the low micromolar range to induce significant 
G2/M phase arrest. This makes detection of subtle concentration-response changes in the 
presence of mutant βI-tubulin more difficult, along with consuming far more drug of 
interest. Natural products such as Pel A and Lau are scarcely available for research purposes, 
thus the challenge of introducing genetic manipulations in mammalian cells is justified. 
2.1.2 Introduction to transfection and exogenous gene expression 
In order to introduce βI-tubulin subunits containing the D297I point mutation into the cell 
model, this study made use of standard cationic lipid-based transfection methods. Episomal 
sequence encoding the mutant βI-tubulin of interest expressed contiguously with a small 
green fluorescent protein (GFP) variant was utilised as a marker for successful transfection, 
and to monitor aspects of both mutant abundance and microtubule morphology.  Plasmid 
DNA encoding sequences of interest may be introduced to cationic lipid-based transfection 
reagents to form transfection complexes that may move into cells by mechanisms of 
endocytosis. For a thorough review of transfection as an approach for introducing 
exogenous DNA to cells, see Chesnoy and Huang (2000).  
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2.1.3 Predicted interactions of Pel A/Lau with βI-tubulin 
 
 
 
 
Based on the crystallographic studies of Prota, Bargsten et al. (2014), both Pel A and Lau 
interact with β-tubulin in a binding pocket defined by amino acid residues Q293, F296, 
P307, R308, Y312, V335, N339, Y342 and F343. Within this region, Pel A is predicted to 
interact via hydrogen bond formations with amino acids S298, D297/R308, R308, Q293 
and Y312 by oxygen atoms O1, O2, O3, O11 and O24 respectively. Similarly, Lau is 
proposed to associate via the formation of hydrogen bonds between amino acids N339, 
D297/S298 and oxygen atoms O9 and O20, along with an additional water-mediated 
hydrogen bond interaction between O27 and the free hydroxyl present in the side chain of 
Y312 (Prota, Bargsten et al. 2014).  
 
The D297I point mutation was selected for investigation based on insights from 
computational analysis and docking studies initially carried out by Huzil, Chik et al. (2008) 
and Khrapunovich-Baine, Menon et al. (2011) generated through HDX-MS experimental 
Figure 2.1.1 Binding interactions of Pel A and Lau. Peloruside A (left) and Laulimalide (Right) 
within the predicted Pel A/Lau binding region of β-tubulin. Models proposed by Prota, Bargsten 
et al. (2014) provide a detailed insight into the discrete interaction mechanisms through which 
both Pel A and Lau associate with β-tubulin. D297 is predicted to share hydrogen bond 
interactions between oxygen 2 (O2) of peloruside (left), and oxygen 20 (O20) of laulimalide 
(right). Figure adapted from (Prota, Bargsten et al. 2014) with author’s permission. 
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data. Although selected for investigation before the elucidation of the crystallographic 
structures of β-tubulin in complex with Pel A/Lau ligands by Prota, Bargsten et al. (2014), 
these insights further implicated D297 as functional in ligand binding. Together these 
studies provide a basis for a need to characterise D297 interactions with Pel A/Lau through 
biological investigations, as carried out in the present study. 
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2.1.4 Aims of this chapter  
A) Optimise transfection parameters to maximise tGFP-D297I-βI-tubulin and 
tGFP-βI-tubulin expression throughout a mammalian cell population 
To investigate the role of the D297 amino acid residue in the binding association of Pel 
A/Lau in vitro, a model with ubiquitous point mutant βI-tubulin distribution will most 
accurately reveal changes in concentration-response as a consequence of said point 
mutation presence. This chapter aims to determine transfection parameters for producing a 
model cell population that maximises the distribution of βI-tubulin point mutation in the 
culture as consistently as possible, while avoiding artefacts in cell-sensitivity to drug 
treatment in cell proliferation assays. 
B) Quantify exogenous expression of mutant βI-tubulins in the transfected cell 
population of paired concentration-response experiments 
The second aim of this chapter is to determine the relative abundance of βI-tubulin present 
in the cell population with the tGFP-D297I and tGFP-WT tubulin fusion sequences in order 
to assess the magnitude of changes seen in paired concentration-response experiments. Any 
phenotypic response may be dependent on mutant protein abundance within individual cells 
or alternatively, mutation presence within the population may allow for retention of 
dynamic microtubule behaviours in the presence of a drug.  
 
C) Examine the morphology of mutant tubulin-containing subunits within 
polymerised microtubules 
To support any correlations between mutant βI-tubulin presence and phenotypic changes 
in concentration-response to drug, the introduced mutant βI-tubulin must be functionally 
integrated within microtubules. The third aim of this chapter is to assess exogenous βI-
tubulin by confocal microscopy to determine if point-mutation containing subunits are in 
fact integrated into microtubule structures rather than simply expressed as inactive protein 
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in the cytosol. Microtubules containing mutant elements while involved in regular cellular 
functions suggest the presence of the mutation does not severely hinder these processes, 
lending support for the independent assessment of cell proliferation in concentration-
response studies as a true indicator of changes in drug-protein interaction.   
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2.2.0 Materials and methods 
2.2.1 Compounds 
Peloruside A (Pel A) and laulimalide (Lau) were kindly provided by Associate Professor 
Peter Northcote and Dr Jonathan Singh of the School of Chemical and Physical Sciences, 
Victoria University of Wellington, New Zealand. The marine sponges Mycale hentsheli 
and Cacospongia mycofijiensis were collected from the Pelorus Sound, Marlborough 
Sounds, New Zealand, and ‘Eua and Vava’u, Tonga respectively. Mycale hentsheli was 
utilised as source material for purification of Pel A, and Cacospongia mycofijiensis served 
as raw extraction material for the purification of laulimalide. Once purified, these natural 
products were dissolved at 10 mM in DMSO and stored at -80° C. Paclitaxel was purchased 
from Sigma Chemical Co. (St. Louis, MO, USA) under the trading licence Taxol®. 
Ixabepilone was purchased as Ixempra® from Bristol-Myers Squibb (USA). All 
compounds were stored as 10 mM stock solutions and diluted to 10 µM working stocks in 
RPMI-1640 medium (Invitrogen). All working stocks were stored at -20°C. 
 
2.2.2 Cell culture 
Two cell lines, the human embryonic kidney cell line (HEK293) and the 1A9 cell line, a 
sub-clone of the A2780 human ovarian carcinoma cell line, were utilised in this 
investigation, with each subject to regular PCR-based screening for mycoplasma 
contamination. Sterile culture and maintenance of each cell line was carried out in a Logic 
Labconco® Purifier® Biological Safety Cabinet (Total Lab Systems Ltd, New Zealand). 
HEK293 cells were cultured in DMEM medium (Invitrogen) supplemented with 10% fetal 
calf serum (FCS) (Invitrogen), 2 µM Glutamax™ (Life Technologies) and 100 units/mL 
penicillin/streptomycin (Invitrogen) antibiotic unless otherwise stated. 1A9 cells were 
cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal calf serum (FCS) 
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(Invitrogen), .25 units/mL human recombinant insulin (Sigma Chemical Co. St. Louis, MO, 
USA) and 100 units/mL penicillin/streptomycin (Invitrogen) antibiotic supplementation. 
Cells were grown in 75 cm2 culture flasks (Falcon®, Invitro Technologies) in a humidified 
incubator (SANYO Electric Co., Ltd) at 37°C with a 5% CO2 supplemented air atmosphere. 
Cells were harvested or passaged at approximately 75% to 80% confluence. Flasks were 
aspirated and the cells detached via the addition of 1 mL TrypLE™ Express (Life 
Technologies) followed by a 4 min incubation at 37°. Cells were then suspended in growth 
media and centrifuged for 5 minutes at 300 g to remove the TrypLE™ containing 
supernatant before seeding into new culture vessels. Frozen cell stocks were maintained in 
liquid nitrogen in Cryo. s cryotubes (Greiner Bio-one) at 1x106 cells/ mL in culture medium 
with 10% DMSO as a cryoprotectant. All cell cultures were disposed of within 15 passages 
from the initial recovery from cryogenic storage to maintain genetic integrity over the 
duration of this investigation. 
2.2.3 Mammalian expression vector design and preparation 
The PrecisionShuttle mammalian vector with C-terminal TurboGFP flag pCMV6-AC-GFP 
(Origene Technologies, Rockville, MD, USA) was selected as the backbone expression 
vector for the expression of human tGFP-β1-tubulin in mammalian cells driven by the 
highly active cytomegalovirus promoter (CMV). The single point mutation in amino acid 
residue 297 of the β1-tubulin sequence in plasmid RG203629 (Origene) was introduced 
during cloning processes by Mutagenex (NJ, USA), whereby the selected codon for aspartic 
acid was substituted with isoleucine and the complete construct transformed into E. coli. 
Both mutant tGFP-D297I-β1-tubulin and the parental tGFP-β1-tubulin-transformed 
bacterial cultures were used to inoculate sterile Lysogeny broth (LB) agar (1% Bacto-
tryptone, 5% Bacto-yeast extract 1% NaCl, 1% agar) with 100 μg/mL ampicillin (Sigma-
Aldrich, Auckland, NZ) supplementation. The transformed cells were cultured for 16 h at 
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37° C before the selection of a positive colony. A single colony for each plasmid was 
chosen based on normal features of morphology and resistance to ampicillin, and inoculated 
into 2 mL sterile liquid LB broth supplemented with 100 μg/mL ampicillin in a 15 mL 
Falcon tube and cultured for 16 h at 37° C with constant shaking (Bioline Shaking Incubator, 
Edwards Instrument Company, Australia). Sterile liquid LB medium (250 mL) containing 
100 μg/mL ampicillin supplementation was inoculated with 500 μL of each bacterial 
culture in 500 ml conical flasks and cultured for 16 h in a 37° C shaking incubator. Bacterial 
cultures were concentrated via centrifugation in a SORVALL RC 6+ ultrafuge 
(ThermoScientific) at 5,000 xg for 10 min. The plasmid isolation and purification was 
carried out using a Hi Speed Plasmid Maxi kit (Qiagen, Australia) following the 
manufacturer’s protocol. Plasmid concentration was assessed using an ND-1000 Nanodrop 
spectrophotometer (Thermofisher Scientific). The sample quality was assessed by 
electrophoresis of 2 μL of a 1:100 dilution of plasmid sample in a 1 % agarose gel for 1 h 
at 100 V alongside a known high quality plasmid preparation (plasmid species pFA6a-
hphNT1, (Janke, Magiera et al. 2004)) and a 1kb DNA Ladder (Life Technologies. Fresh 
glycerol stocks of each bacterial strain were prepared by diluting 500 μL of liquid LB grown 
to bacterial saturation in 500 μL sterile glycerol in Cryo. s cryotubes (Greiner Bio-One) 
and stored at -80° C until additional plasmid preparations were required. 
The following figure (Figure 2.2.1) represents the cloned sequence utilised during this 
investigation. WT human βI-tubulin with a contiguous tGFP fusion protein is expressed 
following transfection of the vector containing this sequence, driven by the highly active 
cytomegalovirus (CMV) promoter. Within the vector, antibiotic resistance genes Amp and 
Neo are included to allow clonal selectivity in ampicillin (bacteria) or geneticin 
(mammalian) respectively. A mutated codon corresponding to amino acid 297 was 
introduced into this plasmid.   
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Cloning schematic for the final RG203629 mutation plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.2.1 Cloning schematic for mutation plasmid. Human βI-tubulin sequence within the 
multiple cloning region of The PrecisionShuttle mammalian vector with C-terminal TurboGFP 
flag pCMV6-AC-GFP (Origene). Genomic sequence encoding human β1-tubulin is indicated in 
purple. Sequence indicated in orange corresponds to sites of restriction enzyme digest by SgF 1 
and Mlu 1 used in cloning β1-tubulin sequence into the cassette. Sequence indicated in green 
corresponds to the fluorescent tGFP fusion tag expressed contiguously with the mammalian β1-
tubulin product. Sequence in black represents vector backbone DNA as presented in the visual 
schematic. 
 
 
TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCT
GCCGCCGCGATCGCC 
 
ATGAGGGAAATCGTGCACATCCAGGCTGGTCAGTGTGGCAACCAGATCGGTGCCAAGTTCTGGGAGG
TGATCAGTGATGAACATGGCATCGACCCCACCGGCACCTACCACGGGGACAGCGACCTGCAGCTGGA
CCGCATCTCTGTGTACTACAATGAAGCCACAGGTGGCAAATATGTTCCTCGTGCCATCCTGGTGGATC
TAGAACCTGGGACCATGGACTCTGTTCGCTCAGGTCCTTTTGGCCAGATCTTTAGACCAGACAACTTT
GTATTTGGTCGTCTGGGGCAGGTAACAACTGGGCCAAAGGCCACTACACAGAGGGCGCCGAGCTGGT
TGATTCTGTCCTGGATGTGGTACGGAAGGAGGCAGAGAGCTGTGACTGCCTGCAGGGCTTCCAGCTG
ACCCACTCACTGGGCGGGGGCACAGGCTCTGGAATGGGCACTCTCCTTATCAGCAAGATCCGAGAAG
AATACCCTGATCGCATCATGAATACCTTCAGTGTGGTGCCTTCACCCAAAGTGTCTGACACCGTGGTC
GAGCCCTACAATGCCACCCTCTCCGTCCATCAGTTGGTAGAGAATACTGATGAGACCTATTGCATTGA
CAACGAGGCCCTCTATGATATCTGCTTCCGCACTCTGAAGCTGACCACACCAACCTACGGGGATCTG
AACCACCTTGTCTCAGCCACCATGAGTGGTGTCACCACCTGCCTCCGTTTCCCTGGCCAGCTCAATGC
TGACCTCCGCAAGTTGGCAGTCAACATGGTCCCCTTCCCACGTCTCCATTTCTTTATGCCTGGCTTTGC
CCCTCTCACCAGCCGTGGAAGCCAGCAGTATCGAGCTCTCACAGTGCCGGAACTCACCCAGCAGGTC
TTCGATGCCAAGAACATGATGGCTGCCTGTGACCCCCGCCACGGCCGATACCTCACCGTGGCTGCTGT
CTTCCGTGGTCGGATGTCCATGAAGGAGGTCGATGAGCAGATGCTTAACGTGCAGAACAAGAACAGC
AGCTACTTTGTGGAATGGATCCCCAACAATGTCAAGACAGCCGTCTGTGACATCCCACCTCGTGGCCT
CAAGATGGCAGTCACCTTCATTGGCAATAGCACAGCCATCCAGGAGCTCTTCAAGCGCATCTCGGAG
CAGTTCACTGCCATGTTCCGCCGGAAGGCCTTCCTCCACTGGTACACAGGCGAGGGCATGGACGAGA
TGGAGTTCACCGAGGCTGAGAGCAACATGAACGACCTCGTCTCTGAGTATCAGCAGTACCAGGATGC
CACCGCAGAAGAGGAGGAGGATTTCGGTGAGGAGGCCGAAGAGGAGGCC 
ACGCGTACGCGGCCGCTCGAG - tGFP Tag -----Vector Backbone 
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2.2.4 Transfection optimisation of HEK293 
HEK 293 cells were seeded in 12-well plates at 2 x 105 cells per well in 1.0 mL growth 
medium and allowed to adhere overnight. At approximately 75-80% confluence, growth 
medium was replaced with 900 µL antibiotic-free growth medium and transfection with 
varied quantities of tGFP-β1-tubulin expression plasmid and Lipofectamine 3000® reagent 
(Invitrogen) was carried out to determine optimal transfection conditions. The quantity of 
plasmid DNA for transfection was assessed multiple times before optimisation over a range 
of 0.6 µg-1.0 µg per well by diluting tGFP-βI-tubulin plasmid DNA with P3000® reagent 
(Invitrogen) in a 1:2 ratio (µg DNA: µL P3000®). The mixtures were then diluted up to a 
final volume of 50 µl in Optimem Reduced Serum Medium (ORSM) (Invitrogen) per 
transfection mixture. The optimum quantity of Lipofectamine 3000®  reagent was assessed 
over the plasmid to reagent ratios 1:1, 1:2 and 1:4 µL reagent to µg DNA by diluting the 
Lipofectamine 3000®  in a second tube with a final volume of 50 µl ORSM. After a 5 min 
incubation at room temperature, the diluted Lipofectamine 3000®  was mixed gently with 
the appropriate DNA: P3000®  complex containing tube and incubated for 20 min at room 
temperature to allow complete formation of cationic-lipid complexes. The transfection 
mixture (100 µL) was then added sequentially to each appropriate transfection well giving 
a final volume of 1 mL transfection medium. Cells were then grown for 48 h, and optimal 
transfection conditions were evaluated by examination of GFP expression and cell viability 
using a fluorescence microscope (Olympus IXS1, Olympus, Tokyo, Japan). 
 
2.2.5 Transfection of HEK293 for experimental applications 
HEK 293 cells were seeded in 6-well plates at 5 x 105 cells per well in 1.5 mL growth media 
and allowed to adhere overnight. At approximately 75-80% confluence, media was 
replaced with 1.25 mL antibiotic-free growth media and transfection was carried out with 
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a scaled up version of the optimal protocol determined in section 2.2.4. Specifically, 2 µg 
per well of tGFP-βI-tubulin or tGFP-D297I-βI-tubulin plasmid were added to independent 
reaction mixtures before the addition of 4 µL P3000® reagent per well. The combined 
plasmid DNA and P3000® solution was then diluted to a final volume of 125 µL per well 
in ORSM. A second tube was prepared with 4 µL Lipofectamine 3000® per well diluted to 
a final volume of 125 µL in ORSM. After a 5 min incubation at room temperature, 125 µL 
per well of dilute Lipofectamine 3000®  was gently mixed with each plasmid + P3000® 
tube and incubated for 20 min at room temperature. The final volume of 250 µL per well 
of complete transfection complex was then added to each well giving a total volume of 1.5 
ml transfection medium within each transfection well in the 6-well plate. Cells were then 
grown for 48 h before use to allow exogenous expression levels to reach their maximum. 
Transfection efficiency and cell health were assessed by fluorescence microscopy 
(Olympus IXS1, Olympus, Tokyo, Japan) by imaging the presence of tGFP signal under 
fluorescence and the total cell count under phase-contrast using the 10 x objective. 
Selection using geneticin (G418) was avoided, as preliminary experiments in transfected 
cells expressing the aminoglycoside 3’-phosphotransferase APH3’ II, exhibited 
inconsistent responses in response to antibiotic selection, impacting overall cell health and 
introducing changes in sensitivity to microtubule-stabilisers. Instead of selection in G418, 
the high efficiency transfection protocol described in section 2.2.4 was used to optimise the 
procedure, maintain the health of cells and minimise the proportion of non-transfected cells 
present in the cultures. 
2.2.6 Confirmation of transfection by fluorescence microscopy 
Forty-eight hours following transfection, cells were imaged by fluorescence microscopy 
before treatment with microtubule-stabilising agents in downstream experiments.  The 
same transfected cultures were again imaged at 144 h post-transfection. These images were 
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examined to determine both the transfection efficiency and stability of transgene expression 
within the whole population of cells over time course of the concentration-response studies. 
Six-well plates were imaged using the 10 x objective on a fluorescence microscope 
(Olympus IXS1, Olympus, Tokyo, Japan). An area representative of the sample was 
imaged under the FITC filter upon exposure of the cells to a mercury lamp excitation source. 
An exposure time that limited the visibility of non-transfected cells or debris was used to 
aid in keeping images comparable across transfections. The same field of view was then 
imaged under phase contrast light microscopy. The two images were overlaid using ImageJ 
software (NIH), with the green channel threshold set above background fluorescence. Due 
to the relatively high transfection efficiency obtained by optimisation of the protocol as 
described in section 2.2.4, further quantitative analysis of transfection efficiency by flow 
cytometry was not necessary as tGFP reporter activity was highly consistent and 
widespread throughout the transfected population. A randomised region within each image 
of an equivalent size was selected, with care taken to include at least 100 evenly distributed 
cells. These images were then quantified via the CellCounter plugin for ImageJ with the 
total cell count, and fluorescent cell count recorded to calculate the efficacy of transfection. 
2.2.7 Confirmation of exogenous tubulin expression by western blotting 
Cell samples of transfected 1A9 or HEK293 cells were prepared to correspond to both the 
48 h and 144 h time points of the MTT cellular proliferation assay described in section 
3.2.1. Whole cell samples were collected from cell suspensions by centrifugation of 2 x 106 
cells at 400 g for 5 min in 1.5 ml Eppendorf tubes before aspiration of residual growth 
medium. Cell pellets were then stored immediately at -80° C for later use in expression 
blotting experiments. Cell lysates were prepared from complete sets of cell samples by lysis 
in 60 µL RIPA buffer (25 mM TRIS-HCl, 150 mM NaCl, 5 mM EDTA, .1 % SDS, 1% 
Triton X-100, 1% sodium deoxycholate) containing 10 µL/mL Protease Inhibitor Cocktail 
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I (Sigma-Aldrich, Auckland, NZ). Sample pellets were suspended by brief vortex mixing, 
then placed on an orbital shaker for 30 min at 4° C to ensure complete lysis and suspension 
of total cellular protein. Samples were then centrifuged at 14, 000 g for 20 min at 4° C after 
which the supernatant containing the proteins of interest was transferred to a new 1.5 mL 
Eppendorf tube and the pelleted debris discarded. All samples were kept on ice for the 
subsequent steps. Protein quantification was carried out using the BCA protein assay 
(Thermofisher) following the manufacturer’s instructions. Samples were prepared for 
separation by denaturing SDS-PAGE by diluting 30 µg of lysate protein in 1 x Laemmli 
buffer containing 10% β-mercaptoethanol and Milli-Q water to a final volume of 20 µL. A 
1.5 mm 10% polyacrylamide resolving gel with a 6% polyacrylamide stacking gel was 
loaded with 20 µL of prepared lysate sample per lane including 1.5 µL molecular weight 
ladder (Dual Colour Precision Plus™, Bio-Rad Laboratories) to assist in determining the 
identity of proteins of interest. Surplus cell lysates were stored at -80° C due to the high 
stability of the proteins of interest. Electrophoretic separation of the sample proteins was 
carried out at 120 V for 1.5 h or until complete migration of the dye front through the 
resolving gel had occurred. Proteins were transferred electrophoretically at 4° C for 17 h at 
a constant 20 V to a methanol-activated low fluorescence background PVDF membrane 
(Immobilon-P, Millipore Corp, MA, USA). Following protein transfer, membranes were 
blocked using 5% BSA in PBST (1 x PBS with 0.1% Tween-20 by volume) for 1 h at room 
temperature on a rocking platform. Prior to immunological investigation, membranes 
containing tGFP positive samples were exposed to ambient sunlight for 1 h as an additional 
measure to ensure complete exclusion of tGFP emission spectra during fluorescence 
scanning. Acrylamide gels containing residual proteins were treated for 1 h at room 
temperature with a fixative solution of 50% EtOH and 3% ortho-phosphoric acid (by 
volume) diluted in Milli-Q water. Gels were then washed three times with Milli-Q water 
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before submersion in Coomassie staining solution (0.06% Coomassie® Brilliant blue G-
250 (Biorad Laboratories, Hercules, CA, USA) dissolved in 34% methanol, 17% 
ammonium sulphate and 3% phosphoric acid by volume) and left to develop on a rocking 
platform at room temperature for two days to ensure a complete protein stain before being 
examined for transfer quality. Conditions for immunological probing of blocked 
membranes along with individual experiment control parameters are described in detail in 
the corresponding results sections. All membranes were washed two times between 
antibody incubations with PBST for 10 min at room temperature followed by a third wash 
with 1 x PBS for 10 min at room temperature. Probed membranes were immediately 
scanned using a Fujifilm FLA-5100 Fluorescent Image Analyser (Fuji Photo Film Co. Ltd, 
Tokyo, Japan), and composite images were generated using the MBF-ImageJ software 
(Rasband, W.S., ImageJ, NIH, Bethesda, Maryland, USA). Image densitometry was carried 
out to determine the relative density of membrane bands corresponding to proteins of 
interest by integrating band density areas after adjusting the image threshold values for 
background fluorescence and normalising against the integrated band density area of the 
loading control β-actin. 
2.2.8 Microtubule morphology and confirmation of mutant-tubulin expression by 
live cell confocal microscopy 
Glass bottomed confocal culture dishes (35 mm diameter) were treated with sterile PBS 
containing 500 µg/mL poly-D-lysine hydrobromide (Sigma-Aldrich, Auckland, NZ) for 2 
h. After coating, the solution in the dishes was aspirated and the dish rinsed twice with 
sterile PBS and allowed to dry under UV light within a Logic Labconco® Purifier® 
Biological Safety Cabinet (Total Lab Systems Ltd, New Zealand). HEK293 cells 
transfected with mutant tGFP-β1-tubulin expression plasmids as described in section 2.2.5 
were seeded at 4 x 105 cells in 1 mL growth medium into the freshly coated 35 mm dishes 
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and allowed to adhere overnight. Samples were treated with microtubule-stabilising agents 
Pel A and PTX at 40 nmol/L for 6 h to promote microtubule-stabilisation for comparison 
to control samples. Prior to confocal imaging, the culture supernatant was aspirated and the 
medium replaced with 1 mL fresh growth media that contained 200 ng/mL live cell 
fluorescent nucleic acid counterstain Hoechst 33342 (639, ImmunoChemistry 
Technologies, Bloomington, MN, USA). The stain was aspirated after 45 min, and the 
samples were gently rinsed twice with 1 mL sterile PBS to remove excess stain before the 
addition of 1 mL fresh culture medium, followed by rest for 2 h before confocal imaging. 
Confocal images representing cells in various mitotic states in each sample were captured 
using an Olympus FluoView FV1000 IX81 laser-scanning confocal microscope utilising a 
100 X oil immersion objective (1.45 NA) and a humidified stage top incubator with a 5% 
CO2 in air atmosphere. This allowed for image acquisition at 37° C to prevent aberrant 
microtubule depolymerisation induced by low temperature. Excitation of the Hoechst 
33342 fluorophore used as the nuclear counterstain was achieved using the 405 nm laser 
line with emission capture through the dichrome DAPI 425-460 nm filter set. Excitation of 
the tGFP fluorophore of exogenous βI-tubulin was achieved using the 473 laser line with 
emission capture through the dichrome Alexa Fluor 488 485-545 nm filter set. Images were 
captured in Z-series optical stacks with 2 µm additional image capture above and below the 
image regions of interest. As photobleaching of tGFP and Hoechst 33342 dyes is significant 
when utilised in live cell imaging, imaging scans were set at an appropriate thickness to 
allow rapid acquisition through the sample to gain representative slices depicting 
microtubule morphology and processes typical throughout the culture. 
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2.3 Results 
2.3.1 Assessment of preparation quality of tGFP-βI-tubulin and tGFP-D297I-βI-
tubulin vectors 
Isolates of the two expression vectors (WT and D297I mutant) (7.9 kb) were prepared as 
described in section 2.2.3 and were analysed by agarose gel electrophoresis (Figures 2.3.1 
and 2.3.2). The plasmid preparations were run alongside a high quality pFA6a-hphNT1 
plasmid preparation (1.84 kilobase pairs) as a control in each of the electrophoreses carried 
out. The presence of a single, discrete bright band indicates that the tGFP-βI-tubulin 
expression vector had been successfully isolated with high sequence integrity, as indicated 
by the lack of genomic smearing within the lane. This was comparable to the high quality 
pFA6a-hphNT1 plasmid preparations run as a comparative control. The plasmid 
preparations were quantified by spectrophotometry using a Nanodrop spectrophotometer, 
and the final concentrations were found to be 1.32 µg/μL for the tGFP-βI-tubulin vector 
and 0.53 µg/μL for the D297I-tGFP-βI-tubulin vector. The A260/A280 and A260/A230 
ratios were assessed to determine sample purity. Both plasmid preparations exhibited high 
A260/A280 and A260/A230 ratios of approximately 1.798 and 2.183 respectively, 
indicating each was relatively free of protein and solvent contaminants. Plasmid 
preparations suitable for use in mammalian transfection experiments require high purity as 
protein or solvent contamination associated with transfected DNA can cause significant 
toxicity to the target cells. Both preparations were deemed suitable for use in transfection. 
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1 2 3 4 
Figure 2.3.1 Agarose gel electrophoresis of tGFP-β1-tubulin plasmid. Lane 1: 1kb DNA ladder. 
Lane 2: pFA6a-hphNT1 control plasmid DNA. Lane 3: a 1:10 dilution of pFA6a-hphNT1 control 
plasmid DNA. Lane 4: tGFP-β1-tubulin mammalian expression vector RG203629.  
pFA6a-hphNT1 
 
RG203629 
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1  2 3 4 
Figure 2.3.2 Agarose gel electrophoresis of tGFP-D297I-β1-tubulin plasmid. Lane 1: 1kb DNA 
ladder. Lane 2: pFA6a-hphNT1 control plasmid DNA. Lane 3: a 1:10 dilution of pFA6a-
hphNT1 control plasmid DNA. Lane 4: tGFP-D297I-β1-tubulin mammalian expression vector 
D297I-RG203629.  
 
RG203629 
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2.3.2 Optimisation of transfection in HEK293 cells 
HEK293 cells were transfected with a range of conditions as described in section 2.2.4 until 
final transfection conditions were identified that resulted in high transgene expression while 
minimising cell death (Figure 2.3.3). Excessive lipofectamine 3000® reagent (greater than 
1 µL per well) resulted in substantial cell toxicity (approximately 50% of cells non-viable), 
similarly to conditions where excess plasmid was detrimental to cell health. Lower plasmid 
concentrations resulted in fluorescent signals from individual cells similar to transfection 
with higher plasmid concentration; however, the efficiency of transfection on the total cell 
population was low (approximately 15-25% of cells). Selection with G418 was detrimental 
to the concentration-response of cells in downstream proliferation-assays, whereby large 
variation in IC50 was observed following selection. This prevented selection in G418 as a 
means to enrich the portion of the total cell population expressing mutant βI-tubulin. 
HEK293 cells transfected with 0.8 µg plasmid DNA, 1.6 µL P3000® and 1.6 μL 
Lipofectamine 3000® reagent exhibited the highest transfection efficiency while 
maintaining normal cell morphology. As seen in Figure 2.3.3, a lower plasmid 
concentration resulted in far fewer successfully transfected cells; while higher 
concentrations up to 1.0 μg plasmid DNA were harmful to the cells. The appearance of 
granular debris and very bright round cells indicates cell death, indicative of this toxicity. 
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0.8 μg 
0.6 μg  
  1.0 μg      
Figure 2.3.3 Assessment of transfection optimisations in HEK293 by fluorescent microscopy. 
Images are representative of the changes seen across a changing plasmid concentration with 
2:1 DNA μg to Lipofectamine 3000® in µL. Images captured under phase-contrast are shown 
alongside the same field as viewed through the FITC filter set with tGFP excitation by a 
mercury lamp. Row 1: HEK293 transfected with 0.6 µg tGFP-β1-tubulin plasmid. Row 2: 
HEK293 transfected with 0.8 μg tGFP-β1-tubulin plasmid. Row 3: HEK293 transfected with 
1 µg tGFP-β1-tubulin plasmid. Scale bar =100 µm. Note: Problems with imaging equipment 
at the time of imaging the of 0.6μg plasmid transfection produced the circular exposure.  
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HEK293 transfection with higher levels of Lipofectamine 3000® (6µL/well) as seen above 
in Figure 2.3.4 resulted in a very high number of tGFP-β1-tubulin positive cells; however, 
a large portion of these cells appeared unhealthy, as indicated by changes in their 
morphology. tGFP-β1-tubulin positive cell debris can also be seen throughout the culture, 
suggesting cell death has occurred as a result of Lipofectamine 3000® toxicity. Note: this 
transfection was carried out in a scaled up format and is equivalent to a 0.8 µg plasmid 
transfection in the format of Figure 2.3.3. Transfection under these conditions was not 
appropriate for further experimentation. The final optimised transfection parameters 
utilised in downstream experiments was equivalent to the 0.8 µg/well conditions as seen in 
Figure 2.3.3. 
2.3.3 Confirmation of HEK293 transfection by fluorescence microscopy 
Paired phase-contrast/fluorescence images from both 48 h and 144 h post-transfection of 
tGFP-β1-tubulin and D297I-tGFP-β1-tubulin were used to assess transfection efficiency of 
the cells. Randomised images were quantified as described in section 2.2.6. Typical 
cultures transfected under the optimised conditions were assessed by fluorescence 
Figure 2.3.4 Further assessment of transfection optimisations in HEK293 by fluorescence 
microscopy. The image presented is representative of a typical culture with a high concentration 
of Lipofectamine 3000® used during transfection. Shown here is a transfection carried out using 6 
µL Lipofectamine and 2 µg tGFP-β1-tubulin plasmid in a 6-well format. The image shown was 
capture under phase-contrast which is shown alongside the same field as viewed through the FITC 
filter set with tGFP excitation. Scale bar =100 µm 
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microscopy (Figure 2.3.3, .8 µg plasmid) to determine a quantitative transfection efficiency 
(Figure 2.3.5). There were no significant differences by paired student’s t-test; P>.05 
between each of the two time points (48 h and 144 h) assessed, or between the two plasmid 
species, indicating both plasmids performed similarly. Eight biological replicates were 
assessed, demonstrating a high level of consistency in the efficiency of each transfection. 
 
 
2.3.4 Transfection efficiencies in 1A9 cells 
1A9 cells were transfected as described in section 2.2.5 to assess the suitability of this cell 
line for determining the D297I point mutations effects on cell proliferation with MSA 
treatment. Paired phase-contrast/fluorescence images from both 48 h and 144 h post-
transfection of tGFP-β1-tubulin and D297I-tGFP-β1-tubulin were used to assess the 
distribution of exogenous protein expression in the cultures. The 1A9 cell line exhibited a 
similar transfection profile at 48 h post-transfection compared to the HEK293 cells; 
Figure 2.3.5 Quantification of transfection efficiencies by fluorescence microscopy. Samples 
transfected with either the tGFP-β-tubulin or tGFP-D297I-β1-tubulin expression vectors as 
described in section 2.2.6 were assessed at 48 h and again at 144 h post-transfection to monitor 
the consistency in the portion of the population positive for exogenous gene expression. Data are 
presented as the mean ± SEM of eight biological replicates (n=8). 
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however, the same cultures at 144 h post-transfection demonstrated a significant loss of 
tGFP signal throughout the population. Optimisation of the transfection conditions for 
working with 1A9 cells was discontinued due to the loss of expression at the 144 h time 
point. This post-transfection time is earlier than what would be required for conducting the 
MTT cellular proliferation assay (3-day exposure to the microtubule-stabilising agents after 
an adequate time for adequate exogenous expression).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 h 
 
48 h 
 
Figure 2.3.6 1A9 cells transfected with tGFP-D297I-β1-tubulin expression vector. Images captured 
under phase-contrast are shown alongside the same field as viewed through the FITC filter set. Scale 
bar is indicated in the bottom right frame. Row 1: 1A9 cells transfected with 0.8 µg tGFP-297I-β1-
tubulin plasmid at 48 h post-transfection. Row 2: 1A9 cells transfected with 0.8 µg tGFP-D297Iβ1-
tubulin plasmid at 144 h post-transfection. Note: Transfection conditions were not optimised to the 
same extent as in HEK293 cells due to the early finding that exogenous expression is lost in 1A9 
earlier than that required for cellular proliferation assays to be completed. The bottom right frame 
demonstrates a widespread loss of the tGFP signal throughout the entire culture. Only rare single cells 
remain positive for tGFP expression 144h following transfection. Note the 144 hour image appears 
much darker due to low overall fluorescence in the culture as exposure was kept constant. 
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2.3.6 Confirmation of exogenous tubulin expression by Western blotting: 
Both the exogenous tGFP-βI-tubulins (WT and mutant) and the endogenous βI-tubulin 
content of the HEK293 and 1A9 cell lines was assessed by western blotting to determine 
the relative portion of the total βI-tubulin each tGFP fusion construct represented within 
the transfected cell population. Proteins were prepared for SDS-PAGE as described in 
section 2.2.7 before immunological detection. The primary antibody, mouse anti-βI-tubulin 
(T7816, Sigma-Aldrich, Auckland, NZ) was used at a 1:1000 dilution, with goat anti-mouse 
Alexa Fluor® 488 (A-11001, Life Technologies) at a 1:2000 dilution used as the secondary 
antibody. For a loading control, mouse anti-β1-actin (A2228, Sigma-Aldrich, Auckland, 
NZ) was used at a 1:1000 dilution with the same secondary antibody.  
Cell samples from tGFP-βI-tubulin or the point mutant transfected 1A9 cell cultures 
displayed an approximate 75 kDa band corresponding to expression of a tGFP tagged 
tubulin species (Figure 2.3.7). Below these signals, the smaller endogenous βI-tubulin band 
was detected at approximately 50 kDa, and the βI-actin loading control band at 
approximately 42 kDa. 1A9 samples from the 48 h post transfection time point displayed 
abundant tGFP-tubulin species expression with approximately 54% of the total βI-tubulin 
originating from either expression vector. The corresponding 144 h samples however, did 
not show detectable levels of tGFP tagged tubulin from either vector indicating a loss of 
plasmid expression similar to what was seen for 1A9 cells by fluorescence microscopy in 
Figure 2.3.6. 
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Unlike 1A9, the βI-tubulin expression profile of HEK293 cells following transfection did 
not exhibit this same loss of tGFP-β1-tubulin signal after 144 h. These cells maintained 
their expression of tGFP-tubulin at the 144 h time point, indicating mutant D297I-βI-
tubulin would be present throughout the entire duration of the concentration-response 
studies required. Expression levels of mutant βI-tubulin in transfected HEK293 were 
48 h 144 h 
tGFP-WT tGFP-D297I tGFP-WT tGFP-D297I 
75kDa 
50kDa 
 
Figure 2.3.7 βI-tubulin profile of 1A9 cells samples at 48 h and 144 h post-transfection. A) 
Immunodetection of total βI-tubulin in 1A9 cells after electrophoretic separation of 30 µg protein 
lysate in a 10% polyacrylamide gel. The combined image represents the protein bands of interest 
from two different gels.  Lanes 1, 2: samples transfected with tGFP-β1-tubulin after 48 h. Lanes 3, 
4: samples transfected with tGFP-D297I-β1-tubulin after 48 h. Lanes 5, 6: Samples transfected with 
tGFP-β1-tubulin after 144 h. Lanes 7, 8: Samples transfected with tGFP-D297I-β1-tubulin after 144 
h. At 48 h, both endogenous βI-tubulin and the mutant protein product of each expression vector 
can be seen; however, this same signal at 144 h post-transfection, no exogenous tubulin bands were 
detected.  
B) Summary of βI-tubulin protein abundance data. Densitometry was carried out, and the tubulin 
band densities were normalised relative to the β-actin loading control. Only two biological repeats 
were carried out due to the unsuitable nature of this cell line for further MSA concentration-response 
studies. 
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investigated in much greater depth than in 1A9 cells for these reasons. Mutant βI-tubulin 
bands appeared faintly in preliminary HEK293 immunoblotting experiments, indicating a 
low abundance of exogenous protein expression relative to the total βI-tubulin pool. 
Samples were assessed with two different primary antibodies, one targeting the carboxyl-
terminus of βI-tubulin (T7816, Sigma-Aldrich, Auckland, NZ), and the other targeting an 
alternative epitope located at the amino-terminus of βI-tubulin (1:1000, AAS61557C 
rabbit-anti-h1-tubulin, Antibody Verify, Las Vegas, NV). No significant difference in 
protein abundance was found between the two antibodies, indicating the carboxyl-terminus 
tGFP-tag on the exogenous βI-tubulin species was not likely to be responsible for 
preventing epitope recognition, thus, leading to the low levels of tGFP-tubulin seen. 
 
 
 
Figure 2.3.8 Detection by antibodies targeting the C-vs-N terminus. Presented is a comparison of 
tGFP-D297I-βI-tubulin expression in HEK293 cells as detected by primary antibodies targeting 
epitopes located at either the carboxyl-terminus or amino-terminus of βI-tubulin. Samples taken at 
both 48 and 144 h post-transfection showed no significant difference in the level of detectable 
mutant protein relative to the β-actin loading control when immunoblotting against either epitope in 
βI-tubulin. Data are presented as the mean ± SEM with no significant difference in densitometry 
values found (two-way ANOVA ( n= two biological replicates) 
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Further western blotting was carried out in datasets of 48 and 144 h samples from paired 
dose response assays performed as described in 3.2.1 in an attempt to quantify the relative 
abundance of mutant protein present. As there was no significant difference found between 
the two primary antibodies, the carboxyl-terminus targeting primary antibody (T7816, 
Sigma-Aldrich, Auckland, NZ) was used for all future assessments of relative expression. 
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Figure 2.3.9 A) Mutant expression in HEK293 cells. Presented is the βI-tubulin profile of 
samples transfected with mutant βI tubulin expression vectors taken at 48 and 144 hours post 
transfection. Each set of two lanes represent samples taken from the 48 h followed by the144 h time 
point for a single transfected culture (lanes numbered evenly = 48 h, odd numbers = 144 h). This 
immunoblot represents a typical expression profile from two biological replicates (lanes 1 – 6, lanes 
7 - 12) with indicated bands corresponding to the mutant tubulin species (75kDa), endogenous BI-
tubulin (50kDa) and the β-actin loading control (43 kDa).  
B) Mutant tubulin expression at 48 and 144 h corresponding to paired concentration-response 
studies with MSA treatment. Mutant βI-tubulin expression in transfected cell samples was assessed 
for consistency across experiments. Western blotting was performed for 12 biological replicates 
with samples taken from paired cultures that were used in dose response studies as described in 
3.2.1. 
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Mutant βI-tubulin expression was very low compared to the total βI-tubulin pool in 
HEK293 cells (Figure 2.3.9). After accounting for a data skew caused by a single tGFP-
D297I-βI-tubulin sample with expression much higher than the majority of the biological 
replicates, the level of difference in mutant-βI-tubulin expression between samples was not 
statistically significant. Expression was consistent at both 48 h and 144h (1-way ANOVA 
(p = .057 at a 95% confidence interval)). 
2.3.5 Microtubule morphology and conformation of mutant-tubulin expression 
using live cell confocal microscopy 
The ability of mutant tGFP-βI-tubulin subunits to integrate normally into quaternary 
microtubule structure is critical to understanding the functional significance of the 
introduced D297I point mutation, or indeed the WT tGFP tagged βI tubulin alone. For this 
reason, the presence of tGFP-βI-tubulin in polymerised microtubule structures was 
assessed by live cell confocal microscopy. HEK293 cells transfected with either of the 
tGFP-βI-tubulin vectors exhibited strong tGFP signals in the confocal microscope (Figure 
2.3.9). The appearance of regular, linearized signals within cells was indicative of 
polymerised microtubule structures, as fusion tagged βI-tubulin subunits were incorporated 
into the quaternary microtubule structure. Cells were observed in different stages of mitosis, 
with various image slices indicating the presence of bright, condensed mitotic tubulin 
structures. These condensed structures represent the centrosome, with dense signals 
corresponding to an abundance of correctly integrated tGFP-fused βI-tubulin subunits. Co-
localised to these areas, dense nuclear DNA was observed through a strong Hoechst 33342 
fluorescence indicating the presence of condensed chromosomal DNA. The presence of 
these features within the HEK293 cells suggest mutant tGFP-βI-tubulin is integrated 
correctly into polymerised microtubules which maintain a morphology and physiological 
activity.   
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Figure 2.3.10 live cell confocal microscopy A) tGFP-D297I-βI-tubulin transfected HEK293 
with polymerised microtubules as visualised by confocal microscopy. tGFP-βI-tubulin 
containing microtubules can be clearly seen within individual z-stack slices in various 
conformations consistent with a normal cellular morphology. Frames presented in A each 
represent a single optical slice captured from individual cell clusters within a tGFP-βI-tubulin 
expressing culture. Slightly punctate signal distribution is present in frames, suggesting some 
level of tGFP aggregation. The blue fluorescent nucleoside stain Hoechst 33342 has been 
omitted for clarity in viewing polymerised microtubule structures. All images in these frames 
are to scale with the scale bar (20 µm) in frame A.  
B) tGFP-D297I-βI-tubulin transfected HEK293 in an end-on view of prometa phase in cell 
division. Dense microtubule structures with integrated tGFP-tagged βI tubulin are visualised 
alongside condensed chromosomal structures (blue) as a part of the centrosome complex 
during cell division. The frame shown on the right depicts a cell with the signal from 
condensed chromosomal structures removed for clarity. Both images are to scale with the 
scale bar (5 µm) presented in the left-hand frame. 
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Cells transfected with tGFP-βI-tubulin appear to express considerable amounts of 
exogenous βI-tubulin; however, quantification by confocal microscopy is not possible from 
these images. While very low levels of  expression of  mutant βI-tubulins were detected 
from whole cell populations by Western blotting (Figure 2.3.9), mutant βI-tubulin within 
individual successfully transfected cells appears as strong tGFP signals evident throughout 
the images captured by confocal microscopy.  
2.4 Discussion 
Expression of tGFP-D297I-βI-tubulin  
The research presented within chapter two of this investigation focused around the 
introduction of a D297I-mutant-βI-tubulin isoform with regular biological function into a 
mammalian cell model. In order to assess the biological significance of the hydrogen-
bonding interaction between the βI-D297 amino acid residue and Pel A or Lau, as predicted 
by x-ray crystallography (Prota, Bargsten et al. 2014), our mutant construct needed to be 
assessed  for suitability in this investigation. tGFP-D297I-βI-tubulin subunits present 
within transfected cultures, under ideal conditions, would represent the entire βI-tubulin 
pool of the cells. In this scenario, any change in the molecular interaction of Pel A or Lau 
with the D297I mutant residue would be revealed through large shifts in the proliferative 
drug response phenotype of the cells. 
Transfection of the 1A9 cell line with the D297I-βI mutation construct provided widespread 
transgene expression throughout the cell population, even without significant optimisation 
of the transfection parameters. tGFP-D297I-βI-tubulin expression was robust, with a high 
abundance of mutant tubulin in Western blots by 48 h. Unfortunately, transfected 1A9 cells 
also demonstrated an almost complete loss of this mutant expression in both Western blot 
and immunocytochemistry studies 144 h following transfection. This indicated that mutant 
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βI-tubulin subunits were unlikely to be present over the complete time course of any 
concentration-response experiments for IC50 estimation. Stability in the level of exogenous 
βI-tubulins present within a cell population is key to interpretation in an in vitro model, if 
a good correlation is to be made between mutant tubulin levels and IC50 values. 
As a result of the early loss of expression, 1A9 cells were unsuitable for concentration-
response studies despite the high abundance of mutant βI-tubulin present early on. Like 
1A9, the HEK293 cell line also demonstrated widespread expression of transfected mutant 
and WT tubulin; however, unlike 1A9 cells, the transfected HEK293 cultures maintained 
their expression of tGFP-D297I-βI for 144 h, indicating this cell line would be more 
suitable for use in the in vitro model. Surprisingly, however, the fraction of the βI-tubulin 
pool made up by mutant-βI subunits was found to be substantially lower than that found in 
the 1A9 cell line by Western blotting. A lower abundance of mutant βI-tubulin expression 
would certainly reduce the magnitude of any potential changes in proliferative activity in 
response to Pel A or Lau, seen as the direct result of introducing the D297I-mutant-βI-
tubulin.  
In earlier studies of Pel A and Lau binding associations, a sub-clone of the 1A9 cell line 
(L4) was generated in Dr Paraskevi Giannakkakou’s lab at Weil Cornell Medical College 
through long-term selection in the presence of Lau (Kanakkanthara, Wilmes et al. 2011). 
This cell line demonstrated a 39-fold increase in resistance to both Lau and Pel A compared 
to the parental 1A9 cell line. Point mutations R306H or R306C in the βI-tubulin amino acid 
sequence within clones of the L4 cell line implicated this region’s importance in the drug-
protein association of Lau and Pel A, providing the first mammalian cell-based evidence 
for the βI-tubulin-binding site. A second 1A9 clone (R1) generated similarly by long-term 
culture with increasing exposure to Pel A exhibited the point mutation A296T within the 
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βI-tubulin amino acid sequence, conferring a 6-fold resistance to Pel A with no notable 
alteration in Lau sensitivity. The resistance to Lau and Pel A,f1 especially in the L4 clone, 
is a prime example of the large shift in concentration-response a single point mutation can 
confer when the mutation is present within the whole βI-tubulin complement of the cell 
population.  
In the present study, transfected HEK293 cells expressing mutant βI-tubulin demonstrated 
only a small portion of mutant relative to endogenous βI-tubulin content; however, previous 
studies on the effect of βI-tubulin point mutations on PTX resistance found differential 
resistance to PTX with approximately 5% exogenous βI-tubulin expression (Wang, Yin et 
al. 2006). The magnitude of these changes was expected to be significantly lower than the 
39 fold difference seen in the L4 cells. This is not surprising, given the relatively low tGFP-
βI-tubulin abundance in the cells. 
Approximately 60% of HEK293 cells within the population expressed mutant βI-tubulin, 
with a high consistency in expression, albeit at very low abundance based on Westerm blot 
quantification. It was decided however that because of the stable abundance of the mutant 
tubulin over the necessary 144 h time course for an IC50 determination; the HEK293 cell 
line was suitable for investigation of the importance of the D297 amino acid residue in Pel 
A or Lau binding interactions. Even a small change in concentration-response resulting 
from the presence of this mutation would possibly be detected in MTT-proliferation data 
due to the highly consistent behaviour in aspects of transfection, expression and 
proliferation seen in transfected HEK293 cells. 
Additionally, if the presence of the D297I mutant βI-tubulin caused resistance in 
individual cells, it is reasonable to expect this would enrich the proportion of mutant βI-
tubulin expressing cells in the population through a proliferative advantage of these cells 
in drug-treated conditions. Over the complete time course of 144h in concentration-
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response studies, there is potential for successfully transfected cells to increase their 
proportion in the total cells over time. Cells that were less resistant due to less mutant 
tubulin expression would more readily undergo drug-induced apoptosis.  
Rationalising the abundance of tGFP-D297I-βI-tubulin expression in HEK293 cells 
The 1A9 cell line was shown to express tGFP-βI-tubulins in relatively high abundance, 
although this expression was not detected by Western blotting or immunocytochemistry at 
144 h following transfection. Loss of transgene expression from episomal DNA both in 
vitro and in vivo is widely acknowledged. This loss is mediated through nuclease activity 
or remodelling of chromatin architecture (Hasse, Schulz et al. 1992, Bishop, Ramalho et al. 
2006, Riu, Chen et al. 2007) particularly within expression constructs utilising a viral 
promoter sequence to drive protein expression (Qiu, Leung et al. 2011). Retention of 
episomal expression over time is highly variable between cell lines due to differences in 
the activity of plasmid degradation processes, along with differences in the rates of plasmid 
dilution through cellular proliferation. Rapidly proliferating cell lines such as HEK293 and 
1A9 undergo comparatively short mitotic cycles, depleting the plasmid copy number at a 
greater rate than cell lines with lower proliferative characteristics. This contributes to the 
earlier loss of episomal expression than that seen in other cell lines with a lower 
proliferative capacity. A combination of these properties specific to the 1A9 cell line may 
have led to the high rate of episomal expression loss seen in cultures transfected with our 
particular tGFP-D297-βI-tubulin overexpression construct. 
It was surprising that the relative mutant βI-tubulin abundance, when measured by Western 
blot, was lower than expected given that HEK293 cells are widely considered an excellent 
cell line for overexpression studies. The presence of the tGFP-fusion tag on the carboxyl-
terminus of the βI-tubulin monomer was suspected of causing a disruption in epitope 
recognition by the primary antibody, but assessment with an alternative primary antibody 
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specific for an amino-terminus antigen showed no significant difference in the βI-tubulin 
expression profile. Western blot data obtained under these experimental conditions may not 
have produced true representations of the actual tGFP content in these transfected cultures. 
Fusion proteins are susceptible to cleavage during storage of protein lysates, even with the 
addition of appropriate protease inhibitors. As cell samples were stored at -80 °C before 
complete sets were examined by western blotting, potential breakdown of fusion-tagged-
βI-tubulin may have reduced the total tGFP-βI-tubulin detected by immunoblotting. 
Denaturing acrylamide gels were examined for free tGFP fluorescence (i.e. cleavage 
products of tGFP- βI-tubulin) by scanning for GFP fluorescence: however, signal was not 
detected in the expected 25kDa region where GFP should migrate. This was likely due to 
the linearisation of tGFP tertiary protein structure during lysis and separation by SDS-
PAGE, removing the conformational arrangement required for fluorophore activity. 
Alternatively, levels of detected βI-tubulin may have been reduced during lysate 
preparation as over expression products have a tendency to saturate protein folding 
mechanisms, leading to agrosome formation and activation of protein stress responses 
(García-Mata, Bebök et al. 1999). The presence of low level punctate tGFP expression 
observed within some cells in confocal imaging (Figure 2.3.10) suggests overexpression of 
tGFP-βI-tubulin in HEK293 cells may generate a low level of insoluble aggregates. 
Insoluble aggregates would have been removed during clarification of the cell samples and 
removal of lipid components and other undesired cellular debris. The level of tGFP 
aggregates may also increase during the lytic process and subsequent preparation for 
immunoblotting as the presence of detergents and reducing agents pull tGFP-βI-tubulin out 
of a soluble conformation. This is another possible reason that the level of mutant 
expression in HEK293 cell samples appeared to be lower than expected. 
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Endogenous tubulin synthesis is highly responsive to autoregulatory feedback and the 
introduction of exogenous tubulins by transfection (Gonzalez-Garay and Cabral 1995). 
The stoichiometric requirement of α-β-tubulin heterodimer formation means free βI-
tubulin in the cytosol is rapidly degraded after synthesis if not incorporated into a dimeric 
configuration. Additionally, fusion constructs display comparatively shorter turnover 
times than endogenous isoforms, which exhibit greater stability in an unperturbed system. 
This factors, combined with a potentially enhanced βI-tubulin turnover from the 
disproportionate stoichiometry of overexpression products contribute to the possibility 
that the low tGFP-βI-tubulin signal detected in Western blot analysis may under represent 
the contribution of exogenous βI-tubulin in the system.  
Functionality of tGFP-tagged-βI tubulin in a biological context 
Confocal microscopy of live HEK293 cell cultures allowed for a visual assessment of 
mutant βI-tubulin subunits in their native physiological environment. Before correlating the 
presence of D297I mutant βI-tubulins to any potential shift in concentration-responses 
observed following treatment with Pel A or Lau, transfected HEK293 cells were examined 
morphologically. The mutant βI-tubulin subunits had the potential to disrupt normal 
microtubule dynamics; thus, an examination of microtubule polymers with tGFP-tagged 
βI-tubulin integrations was important. Polymerised microtubules were observed with both 
tGFP-βI-tubulin and tGFP-D297I-βI-tubulin integration into the microtubules, in addition 
to functional associations with physiological structures such as the centrosome complex 
and the chromosomes. As normal microtubule morphology was seen, the presence of the 
25 kDa tGFP tag did not likely perturb biological function within the system. Mutant βI-
tubulin subunits were readily incorporated into microtubule polymers, and were not simply 
present within the cytosol, lacking appropriate biological activity. In other studies utilising 
the same pRCHAβI plasmid (Wang, Tian et al. 2006) to introduce a small 9-amino acid 
hemagglutinin (HA) epitope-tubulin fusion protein noted that the presence of this sequence 
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did not alter the biological function of the tubulin subunits, nor processes of dynamic 
equilibrium.  
In conclusion, the HEK293 cell line was validated as a suitable biological system for use 
in our investigations of the D297 amino acid residue and its predicted molecular 
interactions with Pel A or Lau. The 1A9 cell line demonstrated higher levels of mutant βI-
tubulin expression; however, the transient duration of expression severely limited the scope 
of this cell line for use in our investigation. A larger shift in potential concentration-
responses would be expected in a system with greater mutant βI-tubulin presence; however, 
the highly consistent nature of results seen in HEK293 cells was considered a more valuable 
parameter for the assessment of concentration-response shifts resulting from decreased 
PelA or Lau binding affinity. For this reason, transfection of HEK293 cells was optimised 
for application in all further concentration-response studies, making use of a small but at 
least highly consistent introduction of mutant βI-tubulin into the cell population. Cells 
appeared to display no significant alteration in proliferation phenotype in medium 
containing no microtubule-stabilising compound, and demonstrated tGFP-βI-tubulin 
integration into biologically active microtubule polymers. 
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Future directions: 
Improved accuracy in quantification of mutant tubulin 
Western blotting in tGFP-βI-tubulin expression studies revealed mutant protein abundance 
at levels lower than expected for HEK293, a cell line well known for robust expression of 
plasmid-encoded proteins in over-expression studies. This raised questions regarding the 
nature of the tGFP-βI-tubulin expression quantification by Western blotting and whether it 
was in fact, representative of exogenous protein in this model. Immunological probing with 
primary antibodies against epitope recognition sequences at both the carboxy-terminus and 
amino-terminus determined that the presence of the tGFP fusion-tag on βI-tubulin did not 
alter recognition of the target antigen on βI-tubulin, thus was an unlikely reason for the low 
abundance detected for these exogenous proteins. To determine if transfected HEK293 
cells were producing more tGFP-βI tubulin than the immunoblotting suggested, a 
quantitative approach by mass-spectrometry could be utilised in future investigations. 
Peptide mass fingerprint analysis by matrix-assisted laser desorption ionisation-time of 
flight mass spectrometry (MALDI-TOF) represents a powerful technology capable of 
identifying and quantifying the presence of specific protein species within a sample. 
Because the mutant βI-tubulin constructs used in this investigation were constitutively 
expressed with a 25 kDa tGFP fusion tag, peptide fingerprint analysis by MALDI-TOF 
following protein separation by high-performance liquid chromatography (HPLC) is 
possible due to the presence of the unique tGFP peptide sequence on the mutant βI-tubulin 
sequence, but not the endogenous βI tubulin contribution. Traditionally, mass spectrometry 
based methodologies utilising isotope-coded affinity tags (ICAT) have been able to deduce 
the relative abundance of specific proteins in complex mixtures, as was done in a 
microsomal analysis study (Han, Eng et al. 2001). Similarly to ICAT-derived analysis, the 
tGFP-fusion tag on our protein of interest may be utilised in the identification of unique 
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peptide signatures.  Recent advances in LC-MALDI-TOF make peptide analysis of fully 
sequenced genomes (Blackstock and Weir 1999) possible, with complementary validation 
by other proteomic methods offering support for the use of MALDI-TOF in large scale 
quantitative analysis (Hessling, Buttner et al. 2013). 
 
In the present investigation, we were interested in the relative abundance of just two 
specific protein signatures. By making use of the unique peptide fragmentation signatures 
of βI-tubulin, a workflow for comparing the relative frequency of endogenous βI-tubulin to 
tGFP-βI-tubulin within individual chromatographic fractions is possible. Endogenous βI-
tubulin signature events within lighter protein fractions (as defined by molecular weight) 
may be compared directly to equivalent peptide fragmentation signatures detected within 
heavier fractions that correspond to the tGFP-tagged βI-tubulin isotype. Peptide 
fragmentation signatures for tGFP itself would also be represented within heaver fractions, 
allowing a secondary comparison of βI-tubulin/tGFP event frequency. The relative 
frequency of each detection correlates directly to the abundance of each βI-tubulin isotype 
within a sample. Using this approach in future experiments would offer an enhanced level 
of clarity surrounding the nature of plasmid encoded expression, supporting the low 
abundance of tGFP-D297I-βI-tubulin observed or highlighting possible artefacts within the 
immunoblotting approach used in this investigation to estimate the ratio of mutant 1-
tubulin to endogenous 1-tubulin.  
In addition, the detection of free tGFP peptide signatures (25 kDa) within very light HPLC 
fractions would provide some insight into the potential role of tGFP-fusion cleavage from 
plasmid encoded βI-tubulins which may have contributed to the reduced mutant-βI tubulin 
detected by immunoblotting. Once the GFP moiety is cleaved off the mutant tubulin in the 
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cell, the mutant protein would electrophorese with the same mobility as the endogenous 
tubulin and would thus be falsely recognised as endogenous and not transfected 1-tubulin, 
giving an artificially low Western blot estimation of transfected protein relative to 
endogenous. 
 
Generation of a stable transfected cell line 
To further examine the characteristics of mutant βI-tubulin binding interactions with Pel A 
or Lau, the generation of HEK293 cell lines with a stable genomic integration of plasmid-
encoded mutant βI-tubulin sequences would be highly advantageous. A cell line with this 
genetic property would likely improve the resolution of any concentration-response 
investigations due to expression of mutant βI-tubulin throughout the clonal population. 
Likewise, a stable integration of the mutant sequence into additional cell lines such as PTX-
resistant 1A9 cells would allow further characterisation of drug interactions in a more 
clinically relevant model, while avoiding complications surrounding loss of mutant βI-
tubulin expression in the culture over time. 
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Chapter 3. Investigations into the differential drug sensitivity of 
mutant tGFP-D297I-βI-tubulin in HEK293 cells 
 
3.1 Introduction 
The material presented within chapter three of this thesis details the quantifiable changes 
in properties of a cell population after transfection with the mutant βI-tubulin species. These 
assessments were carried out through concentration-response studies and examination of 
alterations in D297I mutant tubulin polymerisation states in the presence of Pel A, Lau, 
PTX and IXA.   
 
3.1.1 Introduction to cytotoxicity screening and cell proliferation assays 
Following the introduction of high-throughput screening methodologies, the number of 
chemical compounds of both synthetic and natural origin that have been shown to exhibit 
bioactive properties is quickly expanding. At present, there are 977,499 individual 
compounds entered in the NCBI Database PubChem Integrated Platform of Small 
Molecules and Biological Activities database (Bolton, Wang et al. 2008, 2014) with 
bioactivity assessments carried out through one or more assay formats. Compounds are 
usually assessed across multiple assay formats, each designed to identify a specific type of 
bioactive property. Compounds demonstrating cytotoxic properties are of particular interest 
for drug development in that these represent potential candidate molecules for the 
development of new therapeutics. Two key bioassay types used in the identification and 
assessment of anti-cancer biomolecules are those designed to measure cytotoxicity or anti-
proliferative characteristics in vitro and provide further characterisation of a compound 
following identification. Compounds Pel A, Lau, PTX and IXA are all thoroughly 
characterised as potent cytotoxic agents with concentration-dependent properties in vitro. 
77 
 
In order to characterise the specific activities of these compounds against cells with a 
mutant protein-target, this study has made extensive use of the reductive properties of the 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium salt (MTT). The MTT cell 
proliferation assay initially described by Mosmann (1983) is a robust, widely applied 
method for the examination of compound-induced growth inhibition in cells, particularly 
in cells with a high correlation between rates of metabolic process and proliferative 
capability. MTT is reduced in the cytosol of cells with functional NAD(P)H-dependent 
oxidoreductase enzymes, although a degree of reductive activity occurs with additional 
cytosolic and membrane bound elements  (Berridge, Herst et al. 2005). This reductive 
capacity may then be correlated to metabolic activity by measuring the optical absorbance 
of the purple formazan product at 570 nm. The intensity of absorbance is a useful indicator 
for cell viability in culture under controlled conditions and thus allows determination of the 
concentration-response of these cells in the presence of compounds of interest. 
3.1.2 Introduction to in situ tubulin dynamics 
As detailed throughout chapter 1, the cytoskeleton is a highly dynamic system undergoing 
constant rearrangements to facilitate necessary cellular processes. Microtubules exhibit 
dynamic polymerisation behaviours, particularly during the major cellular rearrangements 
leading up to and during mitosis. Methods designed to examine the in situ state of tubulin 
polymerisation allow separation of insoluble (polymerised) tubulin fractions from soluble 
(non-polymerised) fractions as an indicator of microtubule polymer activity within a cell 
population. Following treatment with a MTA, the effect of a compound on the dynamic 
equilibrium of tubulin can be examined through observing a shift of tubulin subunits 
between states of solubility. MTAs promote the stabilisation of tubulin heterodimers into 
polymerised microtubules, shifting the dynamic equilibrium of these proteins towards 
favoured presentation in the insoluble tubulin fraction. Giannakakou, Sackett et al. (1997) 
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utilised fractionation of tubulin by solubility state to demonstrate cells with PTX resistance 
showed impaired polymerisation responses in the presence of PTX. In the current study 
this approach is utilised to investigate the solubility state of WT HEK293 cell cultures 
compared to tGFP-D297I-βI transfected HEK293 cells when treated with Pel A, to 
determine whether the presence of this mutation causes HEK293 cells causes inhibition of 
Pel A induced polymerisation-responses. 
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3.2.0 Aims of this Chapter 
A) Evaluate the concentration-response of cells with an expressed D297 point 
mutant βI-tubulin population in response to Pel A and Lau 
The primary aim of this chapter is to evaluate the biological effect of introduced tGFP-
D297I-βI-tubulin mutant subunits on the concentration-response of transfected cell 
populations treated with Pel A or Lau. It was hypothesised that the presence of the D297 
substitution may alter the proliferative response of cells to Pel A and Lau as the result of a 
disruption in normal ligand association within mutant subunits. As a consequence, 
transfected cells will display sensitivity or resistance phenotypes as a result of the presence 
of point mutant βI-tubulin subunits and the magnitude of these changes may differ between 
treatment with Pel A or Lau. This chapter seeks to evaluate the nature of these potential 
responses.  
B) Examine the concentration-response of transfected cells treated with PTX or 
IXA to determine the effect of the point mutations presence, independent of 
direct ligand binding to the D297I substitution.  
A second aim of this chapter is to determine if the presence of the tGFP-fusion tag or point 
mutation in a portion of the total βI-tubulin in the cell population affects the concentration-
response of these transfected cells to MSAs that do not associate directly to βI-tubulin in 
the region of these mutations. This will generate insights into the effects of the mutation on 
global conformation within the tubulin monomer, which has the potential to impact 
concentration-response. This chapter aims to determine if mutant βI-tubulin subunit 
presence alters proliferation in the presence of PTX and IXA, so any changes seen in Pel 
A and Lau treatments are likely the consequence of disrupted ligand interactions at amino 
acid residue 297. 
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C)  Examine microtubule polymerisation states for D297I-βI-tubulin point 
mutation transfected cells in response to Pel A  
The presence of βI-tubulin subunits containing the D297I amino acid substitution may 
display alterations in dynamic behaviours in response to drug treatment by Pel A compared 
to WT cultures. It was hypothesised that the presence of D297I in a portion of the total βI-
tubulin may allow a level of dynamic instability in microtubule polymerisation behaviours 
to be maintained in the presence of drug. This chapter aims to investigate these potential 
alterations and if found, rationalise the contribution of this effect in relation to any changes 
seen in the concentration-response of transfected cells treated with Pel A.  
81 
 
3.3 Materials and Methods 
3.3.1 Cellular proliferation of D297I mutant β1-tubulin HEK293 by MTT in 
response to microtubule-stabilisers 
To assess the anti-proliferative activity of microtubule-stabilising compounds on HEK293 
cells, a standard approach was used to find the concentration of Pel A, Lau, IXA or PTX at 
which 50 % of proliferative activity was inhibited (IC50) as determined by a half log 
concentration-response treatment. HEK293 cells transfected with D297I mutant tGFP-β1-
tubulin or wild type tGFP-β1-tubulin and mock-transfected (treated with Lipofectamine 
3000® only) were seeded in 96-well tissue culture plates (Microtest™ Tissue culture plate, 
Falcon, Becton Dickson) at 1 x 104 cells / well in 100 µL complete growth medium and 
allowed to adhere overnight. Microtubule-stabilising agents were added after a minimum 
of 48 h post-transfection to ensure consistency in levels of exogenous gene expression at 
the time of culture treatment. Cells were treated the following day with the various 
microtubule-stabilising agents by addition of 400 nM compound to the first well in 
duplicate followed by a half-log concentration serial dilution down the 96-well plate. Media 
transfers were carried out as gently as possible so as not to detach any cells. The plates were 
then incubated for 72 h at 37° C before addition of 20 μL MTT (5 mg/mL in sterile-filtered 
PBS). Plates were incubated for 2 h at 37° C to allow the development of purple formazan 
products. Crystalline formazan precipitates were solubilised with the addition of 100 μL 
per well solubilising solution (10% SDS, 45% DMF by volume in Milli-Q water pH 
adjusted by acetic acid to 4.50). After incubation at 37° C overnight, infrared absorbance 
at 570 nm was determined spectrophotometrically using a multiwell-plate reader (Enspire 
2300, Perkin Elmer). Using growth medium-only well absorption as a background, 
untreated control wells served as a baseline for normal cellular proliferation. Cellular 
proliferation of drug-treated samples was calculated via subtraction of the background 
absorbance and expressed as a percentage of the control absorbance adjusted for 
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background absorbance (sample absorbance – background absorbance / untreated 
absorbance – background absorbance) x 100. These proliferation data were utilised to 
generate half maximal inhibitory concentration models using Sigma Plot v.11 (Systat 
Software Inc., Point Richmond, CA, USA) by fitting four parametric logistic curves to a 
log scale of each stabilising agent concentration against the corresponding cellular 
proliferation as a percentage of control.  
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Sigma Plot v.11 utilises the following equation in the generation of these models: 
𝐶𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑃𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛 (% 𝐶𝑜𝑛𝑡𝑟𝑜𝑙) =
𝑀𝑎𝑥 − 𝑀𝑖𝑛
1 + (
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐼𝐶50
)
𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒  
 
Max indicates the maximum measurement and Min the minimal value measured. 
Each of the four compounds, Pel A, Lau, PTX and IXA, were assessed against each of the 
three HEK293 variants (mock-transfected, tGFP-tubulin transfected and the tGFP-D297I-
tubulin mutant transfected) to generate at least seven biological replicates for each cell 
variant/drug treatment combination with each carried out with at least two technical 
replicates. Prior investigations with three to four biological replicates indicated this study 
would benefit from a larger pool of biological replicates to improve on significance of any 
observed changes in concentration-response.  
3.3.2 In situ polymerisation of β1-tubulin containing D297I mutant isotype subunits 
in response to peloruside A 
Cells were transfected in 6-well tissue culture plates as described in section 2.2.5 with 
D297I mutant tGFP-β1-tubulin and allowed to grow to confluence before the growth 
medium was aspirated and replaced with 1.5 mL complete growth medium supplemented 
with Pel A at concentrations of 0, 40 or 100 nM for 16 h. Cells were briefly rinsed twice 
with 1 x PBS before lysis by incubation at 37 °C in the dark with 400 µL hypotonic buffer 
(1 mM MgCl2, 2 mM EGTA, 1% Noniodet P-40 by volume, 50 mM Tris-HCL (pH to 6.8) 
and 10 μL/mL protease inhibitor cocktail I (Sigma-Aldrich, Auckland, NZ) for 5 min. 
Following lysis, polymerised and soluble tubulin fractions were separated by centrifugation 
at 14,400 g for 10 min at room temperature in 1.5 mL Eppendorf tubes. The soluble protein 
content was collected by the transfer of the supernatant to new 1.5 mL Eppendorf tubes and 
the insoluble fraction resuspended in 400 µL hypotonic buffer. All samples were stored on 
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ice during subsequent steps. Samples were prepared for electrophoretic separation by SDS-
PAGE by diluting 16 µL of protein sample with 5x Laemmli reducing buffer containing 
10% β-mercaptoethanol before complete denaturation by boiling at 95° C for 5 min. 
Twenty µL of each sample was run on a 1.5 mm, 10% polyacrylamide resolving gel with a 
6% polyacrylamide stacking gel alongside 1.5 µL of molecular weight ladder (Dual Colour 
Precision Plus™, Bio-Rad Laboratories). Electrophoretic separation of sample protein’s 
was carried out at 120 V for 1.5 h or until the dye front had completely migrated through 
the resolving gel. Proteins were transferred by electrophoresis for 1h 20 min at a constant 
300 mA to a methanol-activated low fluorescence background PVDF membrane 
(Immobilon-P, Millipore Corp, MA, USA). Following protein transfer, membranes were 
blocked overnight at 4° C on a rocking platform using 5% BSA in PBST. Acrylamide gels 
containing non-transferred proteins fixed for 1 h at room temperature in 50% EtOH and 3% 
ortho-phosphoric acid diluted in Milli-Q water. Gels were then washed three times with 
Milli-Q water before submersion in Coomassie staining solution (0.06% Coomassie® 
Brilliant blue G-250 (Biorad Laboratories, Hercules, CA, USA) dissolved in 34% methanol, 
17% ammonium sulphate and 3% phosphoric acid by volume) and left to develop on a 
rocking platform at room temperature for two days before being examined for transfer 
quality. Conditions for immunological probing of blocked membranes along with 
individual experimental control parameters are described in detail with the corresponding 
results sections. All membranes were washed two times between antibody incubations with 
PBST for 10 min at room temperature followed by a third wash with 1 x PBS for 10 min at 
room temperature. Probed membranes were scanned and analysed as described in section 
2.2.7.  
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3.3.3 Secondary assessment of D297I mutant β1-tubulin presence in HEK293 cells 
Immunological detection methods described in section 2.2.7, while able to detect the 
presence of tGFP-tubulins, resulted in a surprisingly low level of tGFP-1-tubulin detected 
and may misrepresent the actual tGFP-D297I content within the cells utilised in 
proliferation assays. As a secondary assessment, tGFP-D297I-tubulin mutant lysates were 
analysed further by western blotting as described in section 2.2.7 with a focus placed on 
the detection of the tGFP fusion sequence rather than 1-tubulin itself. tGFP containing 
samples were transferred to low background florescence (Immobilon-P, Millipore Corp, 
MA, USA) after electrophoretic separation by SDS-PAGE as described previously. 
Immunological probing was carried out using a 1:1000 dilution of mouse anti-tGFP 
monoclonal antibody (TA140041,  Origene Technologies, Rockville, MD, USA) in 1% 
BSA-TBS for 2 h at room temperature followed by the secondary goat anti-mouse 
AlexaFluor® 488 (A-11001, Life Technologies) in 1% BSA-TBS for 1.5 h at room 
temperature. After each antibody incubation, membranes were washed twice in PBST for 
10 min at room temperature, followed by a third 10 min wash in TBS at room temperature. 
The presence of tGFP-1-tubulin in samples was scanned and analysed as described in 
section 2.2.7.  
3.4 Results 
3.4.1 Assessment of transfection impact on HEK293 in response to PTX and IXA 
HEK293 cells transfected with tGFP-βI-tubulin, tGFP-D297I-βI-tubulin or mock 
transfected cells were tested with PTX and IXA using the MTT cell proliferation assay as 
described in 3.2.1. This allowed for changes in drug sensitivity to be assessed in the D297I 
point mutation transfected populations. The D297 amino acid shares no predicted 
molecular interaction with either PTX or IXA, allowing these drugs to be used as negative 
controls for the assessment of any alterations to cell susceptibility to Pel A or Lau, attributed 
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directly to the presence of mutant-βI-tubulin. The D297I point mutation was designed to 
introduce a small, innocuous change to the βI-tubulin amino acid sequence relative to the 
action of a taxoid site-binding drug. However, even this type of modification could result 
in changes to the tertiary protein structure. Since any change of this nature has the potential 
to interfere with a proteins normal biological function, treatment with PTX and IXA offers 
an opportunity to test whether the altered βI-tubulin subunit can shift the concentration-
response profile of transfected HEK293 cells where no change is expected in comparison 
to wild type HEK293 cells. No significant shift in IC50 values with either PTX or IXA was 
observed between either transfection group compared to the wild type mock-transfection 
control (p >0.05, Student’s t-test). This suggested the D297I point mutation does not 
contribute any significant disruption to PTX or IXA drug association with βI tubulin, nor 
does the mutation significantly alter the proliferation characteristics of HEK293 cells 
following transfection. The following figures depict concentration-response curves 
representative of a single experiment for mock-transfection control, tGFP-βI tubulin and 
tGFP-D297I-βI-tubulin transfected cells along with summary data from a minimum of 7 
biological repeats. IC50 values were calculated from four- parameter logistic curves fitted 
to concentration-response data using Sigma Plot v.11.0. 
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Figure 3.4.1 Concentration-response for mock control transfected HEK293 treated with PTX and 
IXA.  
A) Representative concentration-response curves of mock-transfected (lipofectamine only control) 
HEK293 cells with IXA and PTX treatment. Mock-transfected HEK293 cells were treated for 72 h 
with different concentrations (≤ 200 nM of IXA or PTX. Cell proliferation was assessed using the 
MTT assay as described in the methods. 
B) IC50 concentration (nM) of IXA and PTX in mock-transfected (lipofectamine only control) 
HEK293 cells.  The IC50 for mock-transfected HEK293 cells were determined by the MTT assay 
as described in 3.2.1. IC50 data are presented as the mean concentration (nM) ± SEM (n = 7 IXA, 
10 PTX biological replicates).
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Figure 3.4.2 Concentration-response for tGFP-βI transfected HEK293 cells treated with PTX and 
IXA 
A) Representative concentration-response curves of WT tGFP-βI-tubulin transfected HEK293 cells 
with IXA and PTX treatment. WT tGFP-βI-tubulin transfected HEK293 cells were treated for 72 h 
with different concentrations (≤ 200 nM) of IXA or PTX. Cell proliferation was assessed using the 
MTT assay as described in the methods. 
B) IC50 concentration (nM) of IXA and PTX in WT tGFP-βI-tubulin transfected HEK293.  The IC50 
for WT tGFP-βI-tubulin transfected HEK293 was determined by the MTT assay as described in 
3.2.1. IC50 data are presented as the mean concentration (nM) ± SEM (n = 7 biological replicates). 
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Figure 3.4.3 Concentration-response for tGFP-D297-βI mutant transfected HEK293 cells treated 
with PTX and IXA 
A) Representative concentration-response curves of tGFP-D297I-βI-tubulin transfected HEK293 
cells with IXA and PTX treatment. tGFP-D297-βI-tubulin transfected HEK293 cells were treated 
for 72 h with different concentrations (≤ 200 nM) of IXA or PTX. Cell proliferation was assessed 
using the MTT assay as described in the methods. 
B) IC50 concentration (nM) of IXA and PTX in tGFP-D297I-βI-tubulin transfected HEK293.  The 
IC50 for tGFP-D297I-βI transfected HEK293 was determined by the MTT assay as described in 
3.2.1. IC50 data are presented as the mean concentration (nM) ± SEM (n = 7 biological replicates). 
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Figure 3.4.4 Summary of IC50 data for PTX or IXA concentration-response treatments in 
transfected HEK293 compared to mock transfected cells. No statistical significance between 
transfection vector groups was seen for either PTX or IXA treatment, indicating that the presence 
of mutant βI-tubulin does not significantly alter cellular proliferation in response to PTX or IXA 
(unpaired Student’s t-test p > .05). IC50 data are presented as mean concentration (nM) ± SEM (n = 
7 biological replicates). 
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Table 3.4.1 Summary IC50 data for IXA or PTX treated HEK293 cells. IC50 were determined by the 
MTT assay. Data are presented as the mean ± SEM. No significant difference was found between 
the three groups with either drug as assessed by unpaired Student’s t-test (P = >.05) (n = 7 biological 
repeats). 
 
3.4.2 Assessment of transfection impact on HEK293 in response to Pel A or Lau 
As expected, the presence of the D297I mutation within the population had no effect on the 
sensitivity of the cells to the taxoid site microtubule-stabilising drugs IXA and PTX. This 
was expected as the introduced mutation is situated well outside the taxoid binding site on 
β-tubulin. This suggests that any change observed in the IC50 concentration for Pel A or Lau 
treatment in D297I point mutation transfected cultures is likely the result of an altered drug-
tubulin interactions. The following figures depict concentration-response curves for 
treatment with both Pel A and Lau, representative of a single experiment for mock-
transfected control, tGFP-βI tubulin and tGFP-D297I-βI-tubulin transfected cells along 
with summary data from a minimum of 7 biological repeats. IC50 values were calculated 
from four- parameter logistic curves fitted to concentration-response data using Sigma Plot 
v.11.0. 
 
 IC50 (nM) 
Drug Mock-control 
(n = 7) 
tGFP-βI-tubulin 
(n = 7) 
tGFP-D297I-βI-
tubulin (n = 7) 
IXA  6.2 ± 0.3 6.2 ± 0.5  7.6 ± 0.2 
PTX 5.0 ± 0.2 5.0 ± 0.3  5.2 ± 0.2 
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Figure 3.4.5 Concentration-response for mock-transfected HEK293 cells treated with Pel A and 
Lau. 
 
A) Representative concentration-response curves of mock-transfected HEK293 cells treated with 
Pel A and Lau. Transfected cells were treated with Pel A or Lau for 72 before measurement of cell 
proliferation using the MTT assay as described in the methods. B) IC50 of Pel A and Lau in mock-
transfected HEK293 cells.  The IC50 concentrations (nM) for mock-transfected HEK293 were 
determined by the MTT assay. IC50 data are presented as the mean IC50 (nM) ± SEM (n = 7 
biological replicates).  
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Figure 3.4.6 Concentration-response for WT tGDP-βI transfected HEK293 cells treated with Pel 
A and Lau. 
 
A) Representative concentration-response curves of WT tGFP-βI-tubulin-transfected HEK293 cells 
treated with Pel A and Lau. Transfected cells were treated with Pel A or Lau for 72 before 
measurement of cell proliferation using the MTT assay as described in the methods. B) IC50 of Pel 
A and Lau in tGFP-βI-tubulin transfected HEK293 cells.  The IC50 for tGFP-βI-tubulin transfected 
HEK293 cells was were determined by the MTT assay. IC50 data are presented as the mean IC50 
(nM) ± SEM (n = 7 biological replicates). 
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Figure 3.4.7 Concentration-response for tGDP-D297I-βI mutant transfected HEK293 cells treated 
with Pel A and Lau. 
A) Representative concentration-response curves of WT tGFP-D297I-βI-tubulin-transfected 
HEK293 cells treated with Pel A and Lau. Transfected cells were treated with Pel A or Lau for 72 
before measurement of cell proliferation using the MTT assay as described in the methods. B) IC50 
of Pel A and Lau in tGFP-D297I-βI-tubulin transfected HEK293.  The IC50 for tGFP-D297I-βI 
transfected HEK293 cells was determined by the MTT assay. IC50 data are presented as the mean 
IC50 (nM) ± SEM (n = 7 biological replicates). 
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Figure 3.4.8 Summary of IC50 data for Pel A and Lau treatments of HEK293 cells. 
Cells transfected with mock-control (Lipofectamine only), WT tGFP-βI-tubulin or mutant tGFP-
D297I-βI-tubulin expression vectors. HEK293 expressing the mutant tGFP-D297I-βI-tubulin 
exhibit a small but consistent resistance to both Pel A and Lau indicating D297I mutant βI-tubulin 
subunit presence within the total cell population confers a resistance phenotype in response to either 
drug treatment (Student’s t-test ***p < 0.0001 compared to WT transfected tubulin). Data are 
presented as mean IC50 (nM) ± SEM (n = 7 biological replicates). 
 
  
IC50 of Pel  A treated HEK293 transfectants
M
oc
k
I-t
ub
ul
in

tG
FP
-
I-t
ub
ul
in

tG
FP
-D
29
7I
-
0.0
5.0
10.0
15.0
20.0
***
***
Transfection vector
IC
5
0
 (
n
M
)
IC50 of  Lau treated HEK293 transfectants
M
oc
k
I-t
ub
ul
in

tG
FP
-
I-t
ub
ul
in

tG
FP
-D
29
7I
-
0.0
2.0
4.0
6.0
***
***
Transfection vector
IC
5
0
 (
n
M
)
96 
 
HEK293 cells transfected with WT tGFP-βI-tubulin, mutant tGFP-β-tubulin or mock-
control transfected cells were tested with Pel A and Lau using the MTT cellular 
proliferation assay. Mock-control and tGFP-βI-tubulin transfected HEK293 cells showed 
no significant difference in response to either transfected tubulin (p = >0.05 Student’s t-
test), however tGFP-D297I-βI-tubulin-transfected cells demonstrated a small but highly 
consistent resistance phenotype to both Pel A and Lau, indicating drug-tubulin interactions 
may have been impacted in some capacity. The data of Figures 3.3.5 to 3.3.8 and Table 
3.3.2 indicate that expression of the mutant tGFP-D297I-βI-tubulin causes a small but 
consistent increase in the IC50 values for both Pel A and Lau. The changes observed in IC50 
concentrations for Pel A and Lau in HEK293 cells transfected with the D297I point 
mutation are likely to be a result of altered drug-tubulin interactions. Disruption of the 
predicted hydrogen bond interaction between D297 and the O2 hydroxyl of Pel A, or the 
O20 hydroxyl of Lau, was originally hypothesised to impact on the molecular interaction 
between βI-tubulin and these stabilising agents, thus reducing their ability to stabilise 
microtubules in a polymerised conformation.  
 
Table 3.4.2 Summary IC50 data for Pel A and Lau treatment of HEK293 transfection variants. 
Presented here are IC50 data for Pel A and Lau treatment of mock-control, tGFP-βI-tubulin and 
tGFP-D297I-βI-tubulin transfected HEK293 cells.  IC50 for each transfection species were 
determined by the MTT proliferation assay as described in 3.2.1. Data are presented as the mean ± 
SEM of 7 biological replicates with ***p < 0.0001 by Student’s t-test. D297I-βI-tubulin expression 
within transfected cell populations results in a resistance phenotype compared to tGFP-βI-tubulin 
transfected cells. No significant difference between tGFP-βI-tubulin and mock-control transfected 
populations was observed (p > 0.05). 
 IC50 (nM) ± Resistance Ratio 
Compound 
Mock-
control 
tGFP-βI-
tubulin 
tGFP-βI-D297-
tubulin 
𝑰𝑪𝟓𝟎 𝑫𝟐𝟗𝟕𝑰𝜷𝑰 𝒎𝒖𝒕𝒂𝒏𝒕 
𝑰𝑪𝟓𝟎 𝒕𝑮𝑭𝑷𝜷𝑰 𝒄𝒐𝒏𝒕𝒓𝒐𝒍
 
Pel A 12.6 ± 0.8 12.1 ± 0.6 16.0 ± 0.2*** 1.3 ± 0.1 *** 
Lau 3.1 ± 0.2 2.6 ± 0.1 5.4 ± 0.3*** 2.1 ± 0.1 *** 
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3.4.3 Effect of Pel A on in situ polymerisation of β1-tubulin containing D297I mutant 
subunits 
Dynamicity within the cytoskeletal systems of cells is critical to maintaining the normal 
function of many cellular processes. Tubulin α-β heterodimers exist in constant flux 
between soluble and insoluble states as microtubules undergo polymerisation (growth) or 
catastrophe depolymerisation (catastrophe). Treatment of cells with microtubule-stabilising 
agents introduces a major disruption in normal dynamic equilibrium, causing a decrease in 
dynamicity and, at high concentrations, promoting an increase in the polymerised fraction 
of tubulin heterodimers within cells. The in situ polymerisation state of cells can be 
assessed quantitatively (Giannakakou, Sackett et al. 1997) as an indicator for changes in 
drug-tubulin interactions such as that seen in Pel A/Lau resistance of tGFP-D297I-βI-
tubulin-transfected cultures.  Mock-transfected (Lipofectamine only and tGFP-D297I-βI-
tubulin transfected cultures were treated with Pel A as described in section 3.2.2, and the 
polymerised and soluble fractions of tubulin were separated by centrifugation followed by 
SDS-PAGE (Figure 3.3.9). Immunoblotting for βI-tubulin revealed an interesting shift in 
the solubility profile of βI-tubulin between wild type and mutant-βI transfected samples. In 
the absence of Pel A, mock-transfected HEK293 cells had an average soluble βI-tubulin 
fraction of 52.8 ± 1.3 % (n = 4 biological replicates); while, tGFP-D297I-βI-tubulin 
transfected cell samples contained a significantly higher soluble βI-tubulin fraction of 73.6 
± 11.2 % (n = 5 biological replicates mean ± SEM; with unpaired Student’s t test*p < 
0.0001 compared to the mock transfected cells). This trend was observed consistently 
across all three treatment concentrations. Higher concentrations of Pel A led to a higher 
fraction of βI-tubulin in the polymerised fraction in the WT tubulin cells. Cell populations 
transfected with the D297I tubulin mutant, however, displayed an altered drug-tubulin 
response to Pel A compared to mock-control transfected HEK293 cells, indicating a change 
in drug-βI-tubulin interactions., These results suggest that the tGFP-D297I-βI-tubulin 
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expression vector makes a more major contribution than anticipated from the low 
(approximately 5-15%) transfection expression levels in the HEK293 cells. Thus, the 
mutant tubulin may have contributed a larger pool of βI-subunits than first thought. In order 
to alter the soluble fraction of βI-tubulin species to this extent, quantities of mutant βI-
tubulin were potentially far greater than the 5 to 15% detected by Western blot (Fig. 2.3.10). 
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Figure 3.4.9. Representative in situ polymerisation experiment for HEK293 cells treated with Pel 
A. Presented here is a representative immunoblot from a single in situ polymerisation assay in 
HEK293 cells. Mutant tGFP-D297I-βI-tubulin-transfected HEK293 cells and mock transfected 
cells were treated for 16 h with 0, 40, or 100 nM Pel A. The soluble (S) βI-tubulin was 
electrophoresed alongside the corresponding polymerised fraction (P). 
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Figure 3.4.10 In situ polymerisation of HEK293 cells. This figure provides a summary of in situ 
polymerisation of HEK293 cells transfected with the tGFP-D297I-βI-tubulin mutation plasmid after 
16 h treatment with Pel A. Data are presented as the mean ± SEM % of the total βI-tubulin in the 
soluble fraction from 5 biological replicates (*p = <.05). 
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In the mock transfected cells, soluble βI-tubulin content within samples decreased in 
response to higher Pel A concentrations, indicating a greater abundance of βI-tubulin 
subunits stabilised within polymerised microtubules (Figure 3.4.10). tGFP-D297-βI-
tubulin transfected HEK293 cells displayed an altered profile of βI-tubulin polymerisation 
compared to the mock-transfected cells, with a higher abundance of the soluble tubulin 
fraction at all drug concentrations. No significant difference was found in the portion of 
soluble βI-tubulin in tGFP-D297-βI-tubulin transfected samples at 0 or 40 nM Pel A. 
Contrastingly, a significant change was seen in the mock-control between 0 and 40 nM Pel 
A (Student’s t-test, p = .016) indicating the presence of D297I βI-tubulin in transfected cells 
was altering the ability of Pel A to induce polymerisation. Both mock-transfected control 
and mutant transfected HEK293 demonstrate a significant decrease in the soluble βI-tubulin 
fraction after treatment with 100 nM Pel A, however the difference in the percentage 
change within each group did not reach significance when compared to each other. 
 
3.4.4 Secondary re-assessment of D297I mutant β1-tubulin presence in HEK293 
The WT and mutant tGFP-βI-tubulin content of transfected HEK293 cells as  assessed by 
Western blot in section 2.3.6 was considerably lower than the expected values based on 
preliminary experiments in the 1A9 cell line and similar work carried out in our laboratory 
using HEK293 cells (Kanakkanthara, A. unpublished). A number of independent 
observations made here in concentration-response assays, confocal imaging, and 
immunoblotting suggest the total tGFP-βI-tubulin content of transfected cell samples may 
have in fact been more abundant than what was quantified by Western blot (5-15% of total 
βI-tubulin in the cell) in section 2.3.6. In a separate experiment, immunoblotting against 
exogenous tubulins was carried out by targeting the tGFP fusion construct on the exogenous 
βI-tubulin, rather than an epitope present within βI-tubulin itself. Only a single blot of this 
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type was carried out, though samples present within the preparation came from a range of 
different transfection experiments collected over the duration of this research. Due to 
differences in both antibody fidelity and concentration between βI and tGFP-targeting 
primary antibodies, a relative quantification of mutant expression was not the intended 
purpose of this Western blot. All transfected samples were positive for a strong tGFP signal, 
indicating tGFP antigen was present in approximately equal density in each of the mutant 
tGFP-βI-tubulin samples assessed. The intensity of this fluorescence of this GFP signal 
suggests tGFP antigen recognition sites were abundant in the samples, however; any effort 
to quantify mutant βI-tubulin expression is not directly comparable to the signals detected 
in section 2.3.6. Thus, this immunoblot serves only as a small piece of indirect evidence 
questioning the validity of the low abundance of mutant-βI-tubulin detected in section 2.3.6 
using a βI-tubulin specific primary antibody against these fusion sequences.  
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Figure 3.4.11 Secondary reassessment of tGFP presence in tGFP-D297I transfected HEK293. 
Presented here is an immunoblot detecting tGFP  within tGFP-D297I-βI-tubulin transfected 
samples in HEK293 cells. Lane 1: Molecular weight ladder. Lanes 2-9: tGFP-D297-βI-tubulin-
transfected samples corresponding to 8 individual concentration-response experiments at the 144 h 
time point. βI-actin serves as a loading control in each of the sample lanes, and a tGFP-positive 
signal was detected within all samples. The intensity of the tGFP signal was strong in all lanes, 
indicating tGFP-βI-tubulin expression was relatively stable across these 8 particular transfection 
experiments. The signal present is comparatively stronger than that of tGFP-βI-tubulins detected as 
described in section 2.3.6, however it is not possible to directly compare these signals in a 
quantitative manner. 
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3.5.0 Discussion 
The proliferative behaviour of tGFP-D297I-βI-tubulin transfected HEK293 cells in 
PTX and IXA as an indicator of mutant βI-tubulin fidelity in cellular processes 
Before any investigation into the specific role of the D297I point mutation in the predicted 
βI-tubulin binding association with Pel A or Lau, it was critical to determine that the 
introduction of mutant βI-tubulin subunits into HEK293 cells did not alter the proliferative 
phenotype of these cells treated with drugs targeting the taxane region of β-tubulin. The 
introduction of irregular βI-tubulin subunits, including in our case, subunits with tGFP-
fusion tags, had potential to significantly alter the normal concentration-response of cells 
to treatment with PTX or IXA by impacting global cytoskeletal functions. In this study, a 
thorough evaluation of proliferation characteristics in transfected HEK293 cells following 
treatment with PTX and IXA revealed no significant differences between the concentration-
responses of cells containing tGFP-D297-βI-tubulin, tGFP-WT βI tubulin or mock 
transfected cultures. This was expected as the mutated amino acid was a long distance away 
from the taxoid binding site. The concentration-response IC50 values determined for cells 
treated with PTX or IXA were consistent with other reports of low nanomolar concentration 
activities of these drugs in untransfected cells (Hopper-Borge, Chen et al. 2004, Chen, Sun 
et al. 2012, Kathawala, Wei et al. 2014) (Kanakkanthara, A. Victoria University of 
Wellington. Unpublished data.), although PTX and IXA concentration-response data has 
been more fully explored in other cell lines, primarily those derived from cancerous tissue 
such as 1A9 cells (Giannakakou, Sackett et al. 1997, Dumontet, Jordan et al. 2009).  
Drug competition studies carried out in early stages of Pel A and Lau characterisation 
revealed a distinct mode of action from that of traditional stabilising agents with binding 
associations within the well-characterised taxoid binding-region of βI-tubulin (Nogales, 
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Whittaker et al. 1999). Pel A was found to not compete PTX, yet was displaced from 
binding associations by Lau, the conclusion being that Pel A and Lau share the same or an 
overlapping binding region, distinct from the taxoid site (Gaitanos, Buey et al. 2004). Lau 
had been shown previously to not compete with PTX for binding to tubulin (Pryor, O'Brate 
et al. 2002). Multiple modelling studies published in support of a distinct Pel A/Lau binding 
site have characterised this unique binding region over time (Huzil, Chen et al. 2007, Huzil, 
Chik et al. 2008, Bennett, Barakat et al. 2010, Prota, Bargsten et al. 2013, Prota, Bargsten 
et al. 2014).  
The introduced D297I point mutation focused on within this study did not affect cellular 
proliferation following treatment with the taxoid site binding drugs PTX or IXA. This 
suggests the effects of the introduced point mutation are likely localised to a discrete region 
surrounding amino acid residue 297 within the Pel A and Lau binding region. The tGFP-
fusion tag expressed constitutively with the plasmid-encoded βI-tubulin sequence was 
tolerated within heterodimer polymerisation, supported by this same lack of concentration-
response shift between untransfected and WT tubulin transfected cultures after treatment 
with PTX or IXA. 
Amino acid polymorphisms as products of natural or artificially introduced mutations can 
cause significant alterations in protein function, particularly in cases whereby an alteration 
takes place in critical peptide sequences within secondary or tertiary folding motifs, or sites 
of catalytic activity. Additionally, mutations in the unique carboxy-terminal sequences of 
β-tubulin isotypes can affect post translational modifications, thus altering regular 
interactions with microtubule associated proteins (MAPs) (Luduena 1998, Verdier-Pinard, 
Pasquier et al. 2009). A multitude of βI-tubulin point mutations have been identified within 
the literature that impact on polymerisation, stability or function of microtubules (Hari, 
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Loganzo et al. 2006, Kavallaris 2010). This has implications with regard to therapeutic 
options available for treating disease states with drug resistance phenotypes caused by 
specific alterations to drug binding associations within microtubule targets. 
A single mutation can lead to global structural changes at long distances from the site of 
the mutation as the βI-tubulin peptide sequence adjusts to altered electrostatic, hydrophobic, 
and steric interactions, adopting a variant conformation with more favourable 
thermodynamic properties. This alteration may disrupt electrostatic interactions between 
associated protein complexes (Sheinerman, Norel et al. 2000), which is of concern when 
working with a protein such as βI-tubulin that is composed of heterodimer subunits. The 
D297I point mutation in this investigation was designed with consideration given to 
potential destabilizing interactions to reduce the likelihood that an introduced change would 
severely impact the global structure of tubulin, but would rather only alter electrostatic 
interactions between PelA or Lau and amino acid 297. This design was accomplished by 
using molecular modelling software analysis of the Pel A/Lau binding site on 1-tubulin 
(Assoc. Prof Paul Teesdale-Spittle, personal communication). Subsequent to the design and 
construction of the mutant tubulin used in the present study, the x-ray crystallography 
model of Pel A and Lau bound to tubulin became available (Prota, Bargsten et al. 2014). 
The predicted hydrogen bonding interaction between D297 and Pel A or Lau based on the 
x-ray crystallography analysis of Prota, Bargsten et al. (2014) suggested that a substitution 
of aspartic acid by isoleucine would affect the interaction of Pel A and Lau with the binding 
region on tubulin. Isoleucine is a small, non-polar amino acid with similar steric 
characteristics to aspartic acid; however, isoleucine lacks the polar functionality of a 
hydroxyl group within the side chain. This particular substitution would disrupt a 
favourable hydrogen bonding interaction between the O2 atom of Pel A and the associated 
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hydroxyl of the aspartic acid side chain at position 297 of the βI-tubulin peptide sequence. 
Similarly, the O20 atom of the Lau side chain should be able to form a hydrogen bond with 
the hydroxyl group of the aspartic acid side chain. Thus, the isoleucine replacement of 
aspartic acid at residue 297 of tubulin should disrupt the bond associations with both Pel A 
and Lau without introducing any widespread conformational change, as the aspartic acid 
and isoleucine are relatively small amino acids. Thus, localised steric hindrance would be 
avoided and there would be no propagation of these changes through the tertiary βI-tubulin 
structure. The results presented in this investigation demonstrated that HEK293 cells 
transfected with tGFP-D297I-βI-tubulin did not exhibit large-scale changes in proliferative 
phenotype following transfection, indicating minimal disruption in tertiary protein structure 
or function. The D297I point mutation allows for further study into Pel A or Lau binding 
interactions in the region, with any alterations in drug sensitivity attributed directly to the 
disruption of discrete hydrogen bonding interactions and not non-specific changes in global 
conformation. 
tGFP-D297I-βI tubulin-transfected HEK293 cells show resistance to Pel A or Lau 
inhibition of proliferation 
 
The D297I point mutation was demonstrated to have no impact on proliferation of 
transfected cultures treated with taxoid-site targeting drugs. This was consistent with our 
hypothesis, and validated the use of concentration-response data from PTX and IXA 
treatment as a control for global alterations in βI-tubulin function as a result of mutation or 
the presence of the tGFP fusion-tag. Data were collected from 7 biological repeats, in 
duplicate – a total of 14 individual measurements – for each of the conditions, tGFP-βI-
tubulin, tGFP-D297I-βI-tubulin or mock-transfected HEK293 cells under each of the 4 
drug treatments. This large dataset showed consistent responses and allowed even small 
changes in proliferative response to be detected as a result of D297I-tubulin presence in 
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comparison to cell populations with wild type βI-tubulin alone. Evidence presented within 
Chapter 2 of this thesis suggested that the mutant βI-tubulin presence within transfected 
cultures was relatively low; however, the robust nature of the data collected for mock-
transfected and tGFP-βI-tubulin transfected cells allowed the detection of a small drug 
resistance shift in D297I-βI-tubulin-expressing HEK293 cells with treatment by either Pel 
A or Lau. 
In cultures treated with Pel A, the D297I point mutation conferred a 1.3 ± 0.1 fold increase 
in the IC50 of tGFP-D297I-βI-tubulin transfected HEK293 cell cultures relative to the 
mock-transfected control. tGFP-βI-tubulin transfected cultures demonstrated no significant 
change in concentration response, consistent with our hypothesis that expression of tGFP-
WT-βI-tubulin should not impact binding properties within the target region of Pel A. 
These fusion-tagged subunits are expected to behave in a manner equivalent to endogenous 
WT βI-tubulin. In the case of the D297I-mutant tubulin, the small but highly consistent 
drug resistant phenotype obtained provided support for disruption of Pel A binding 
interactions in the region of the point mutation. Within the main macrolactone structure of 
Pel A, the O2 hydroxyl likely functions as an enhancer of stability for Pel A binding within 
the βI-tubulin Pel A/Lau binding pocket. The replacement of aspartic acid with isoleucine 
in our transfected model appears to have disrupted this predicted interaction within the 
mutant homodimers, leading to an altered state of molecular interactions in the binding 
region. The predicted mechanism of Pel A induced microtubule-stabilisation (Prota, 
Bargsten et al. 2014) suggests the binding association of Pel A induces multiple 
conformational shifts within the helical segment of residues Gln294 to Phe296, leading to 
a stabilized one-turn extension of the H9 helix. This in turn, promotes the formation of 
water-mediated hydrogen bonding between PelA and the H9 amino acid residues Gln294 
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and Leu275 and additional stabilisation by hydrogen bonding to residue Asn300. Combined, 
these changes would promote a re-organisation of the M-loop substructure in βI-tubulin.  
The M-loop is an essential structural element within βI-tubulin and is directly involved in 
the association of complete α-β protofilaments during polymerisation mechanics of the 
microtubule (Nogales, Whittaker et al. 1999, Li, DeRosier et al. 2002, Prota, Bargsten et al. 
2013). Pel A-induced conformational change within the M-loop is predicted to reduce the 
thermodynamic requirements for interactions between neighbouring protofilaments, 
leading to enhanced polymerisation dynamics and stability in extended microtubule 
polymers. Any loss of these interactions would therefore decrease the ability of Pel A to 
cause microtubule-stabilisation, conferring resistance to the cell expressing the D297I 
mutant tubulin. Thus, the small shift in IC50 of Pel A is likely a result of a decrease in the 
compounds ability to induce organisational changes within the M-loop of an individual βI-
tubulin subunit in the presence of the D297I point mutation. This may result in a reduced 
level of drug-enhanced interprotofilament associations throughout the macrostructure of 
the microtubule. 
With Lau, HEK293 cells transfected with tGFP-D297I-βI-tubulin were found to have a 2.1 
± 0.1 fold increase in IC50 value relative to the mock-transfected control. tGFP-βI-tubulin 
transfected cultures again demonstrated no significant alteration in concentration-response, 
providing further support for the retention of normal function of tGFP-βI tubulin subunits. 
The highly consistent shift reflected in concentration-response data of cultures transfected 
with tGFP-D297I-βI-tubulin reinforces the role of the D297 residue in the formation of Lau 
binding interactions. Hydrogen bonding interactions by D297 with the O20 hydroxyl group 
in the side chain of Lau, as predicted by Prota et al., 2014, are disrupted in mutant βI-tubulin 
subunits presenting the non-polar isoleucine residue, leading to a reduction in compound 
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binding stability within the region. This would reduce the ability of Lau to induce 
organisational changes in the M-loop of βI-tubulin and reduce the extent of the enhanced 
protofilament interactions predicted to occur in wild-type βI-tubulin by treatment with Lau. 
The higher fold-change of Lau resistance relative to Pel A in cultures presenting with the 
D297I mutation suggest D297 has a more central role than Pel A in stabilising the binding 
association of the compound and inducing M-loop re-organisation. 
The introduction of tGFP-D297-βI-tubulin reduces intracellular polymerisation in the 
presence of Pel A 
To determine whether the presence of mutant D297-βI-tubulin subunits affects Pel A-
induced tubulin polymerisation, an in situ assessment of tubulin solubility was carried out 
in transfected HEK293 cells. Induced microtubule polymerisation was evaluated after 16 h 
Pel A treatment by examining the relative abundance of βI-tubulin in the soluble and 
polymerised tubulin fractions. In mock-transfected cells, treatment with 40 nM Pel A 
resulted in a 20.9 ± 4.1% reduction in the abundance of βI-tubulin detected within the 
soluble protein fraction compared to untreated cells. This is the result of a shift in 
polymerisation dynamics favouring the formation of insoluble tubulin polymers, stabilized 
in the presence of Pel A. In tGFP-D297I-βI-tubulin transfected cells, this same shift 
polymer formation was not observed, with no significant difference in the portion of βI-
tubulin detected in the soluble fractions between treatments at 0 or 40 nM Pel A. This 
indicates that the D297I point mutation present within a portion of βI-tubulin subunits 
interfered with the level of Pel A-induced microtubule-assembly seen in mock-transfected 
cultures. A strong correlation exists between this observation and the higher IC50 value for 
Pel A, suggesting D297I-βI-tubulin subunits induce resistance to Pel A.  
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At a concentration of 100 nM, Pel A induced a significant level of tubulin-assembly in both 
the mock and tGFP-D297I-βI-tubulin transfected cultures. The IC50 values for inhibition of 
growth of mock and D297I mutant transfected cultures were determined to be 12.6 ± 0.8 
and 16.0 ± 0.2 nM, respectively. It is not surprising, therefore, that a significant level of 
tubulin polymerisation was observed in both cultures as the concentration used of 100 nM 
is several-fold above the IC50. The D297I point mutation is likely to alter the binding 
affinity of Pel A in the predicted binding region, reducing the level of organisation induced 
in the M-loop of βI-tubulin.  
 
Surprisingly, the percentage of soluble βI-tubulin in untreated cells varied significantly 
between the tGFP-D297I-βI-tubulin and mock-transfected cells (73.6 ± 11.2 % and 47.8 ± 
6.0 % respectively). Transfection with plasmid-encoded βI-tubulins appeared to reduce the 
number of polymerised microtubules in the cells; however as an alternative hypothesis, this 
observation could support the idea that higher levels of plasmid-encoded mutant βI-tubulin 
are present than was detected by Western blot. Protofilaments made up of α-β-tubulin 
heterodimers are arranged in a highly organised structure in the dynamic process of forming 
the polymerised microtubule structure. Before soluble (S) βI-tubulin can shift to the 
insoluble tubulin fraction (P), it must associate with α-tubulin in a 1:1 stoichiometry to form 
the heterodimer. In conditions of βI-tubulin overexpression, the relative abundance of α-
tubulin monomers does not satisfy the requirements for complete heterodimer formation, 
preventing a fraction of βI-tubulin from contributing to microtubule polymers. This is put 
forward as a proposed explanation for the observation of a greater proportion of insoluble 
βI-tubulin seen across all three concentrations of Pel A. Interestingly, the bands 
corresponding to a molecular weight of 75 kDa (GFP-tubulin) were not observed within 
any in situ polymerisation experiments, although lysates were prepared from highly 
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fluorescent, transfected cultures as assessed by microscopy prior to sample preparation. 
This is not consistent with the detection of tGFP-βI-tubulins by immunoblotting described 
in Chapter 2 of this investigation. The method of in situ lysate preparation for the analysis 
of tubulin polymerisation profiles varies significantly from the standard Western blot 
procedure used to detect plasmid-encoded expression levels, suggesting that at some stage 
during the in situ polymerisation process, it is possible that the tGFP peptide sequence is 
lost from some or all of the exogenous transfected βI-tubulins; hence, the absence of the 75 
kDa GFP-tubulin band. To prevent this occurring, the electrophoresis sample was not 
boiled prior to loading on the polyacrylamide gel, but some other step in the preparation of 
the samples for electrophoresis may be involved. 
Independent assessment of the presence of tGFP in transfected cultures supports the 
need to quantify mutant βI-tubulin expression by an alternate method 
As a brief check on tGFP protein in the electrophoretic gels, eight tGFP-D297I-βI-tubulin 
transfected cell sample lysates from the 144 h time point of concentration-response studies 
were analysed by immunoblotting for the presence of tGFP specific antigens using an anti-
tGFP primary antibody and a fluorescent secondary antibody. Bright signals at 75 kDa were 
detected, corresponding to the presence of tGFP-βI-tubulin species as expected within the 
lysate. However, there was no band seen at 25 kDa to indicate loss of the GFP tag during 
the preparation of the sample for electrophoresis; one hypothesis for the low abundance of 
mutant protein detection by western blotting. The same fluorophore-conjugated secondary 
antibody was applied as in earlier immunoblotting experiments, but appeared to have a 
surprisingly strong signal with primary antibodies targeted to tGFP antigens as opposed to 
βI-tubulin. The specific activities of each primary antibody, along with variation in the final 
concentration of the reagents, prevents direct comparison of the fluorescence-signal output 
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within each experiment type; however, it is important to acknowledge the stark contrast 
seen between experiments. This observation supports the idea that mutant βI-tubulins may 
have been present in higher abundance than detected by Western blot using primary anti-
I-tubulin antibodies. This supports a need for future application of a proteomics-based 
approach to quantify mutant βI-tubulin expression as discussed in Chapter 2. The small 
resistance phenotype seen with Pel A and Lau induced by the presence of the D297I 
mutation in exogenous βI-tubulin clearly indicates an altered state of drug-binding; 
however, the significance of this altered drug binding needs to be better correlated to the 
relative abundance of the mutant residues. If the mutant D297I residue is in fact only 
present at very low levels, as suggested by the Western blot of lysates from transfected 
cells, then the altered drug-binding affinity of this mutation may induce a far greater change 
in drug-sensitivity to Pel A or Lau when present at higher levels in the cells.  
Aspartic acid 297 of βI-tubulin has a functional role in Pel A and Lau binding-
associations 
Publications on various tubulin point mutations conferring drug-resistance phenotypes are 
widespread in literature, covering both mammalian and yeast models. Cancers resistant to 
traditional taxoid-targeted microtubule-stabilisers do so through a range of mechanisms 
including the upregulation of drug efflux processes (Gottesman 2002), adaptation of tubulin 
isotype content (Burkhart, Kavallaris et al. 2001) or point mutations that directly impact 
compound binding affinities (Giannakakou, Sackett et al. 1997, Begaye, Trostel et al. 2011, 
Kanakkanthara, Wilmes et al. 2011). By modelling βI-tubulin point mutations, we saught 
to elucidate the discrete molecular mechanics of small molecule interactions within their 
targets and the ability of these molecules to induce changes in microtubule polymerisation 
and depolymerisation. By defining the relative importance of particular drug-amino acid 
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interactions, the efficacy of small molecules may be greatly enhanced by rational design-
focused synthetic chemistry.  
 
Historically, microtubule-targeted agents have served as critical front line therapeutics in 
the treatment of hyper-proliferative disease states such as those seen in cancers.  These 
chemotherapeutics will maintain clinical relevance until further advances in the biomedical 
sciences deliver even more targeted clinical solutions for the deeper, underlying cause of 
these diseases. Until such time, any insight into the mechanisms by which current 
therapeutic strategies may be improved are of high value. Although clinical testing has not 
yet begun for Pel A and Lau, the Pel A/Lau binding region of βI-tubulin represents a 
valuable opportunity for the development of potential therapeutics, especially for use in 
cancers with drug-resistance phenotypes against the compounds currently in clinical 
application. Pel A is a poor substrate for P-glycoprotein drug efflux pumps and avoids the 
complication of drug-resistance conferred by point mutations in the taxoid binding-region 
of βI-tubulin (Gaitanos, Buey et al. 2004). Likewise, Lau shares these characteristics in cell 
lines with drug resistance phenotypes (Mooberry, Tien et al. 1999, Pryor, O'Brate et al. 
2002). Recent advances in the characterisation of the binding region shared by these 
compounds provides the necessary starting point for biological verification of drug-target 
interaction mechanics. 
 
Amino acid D297 was predicted by x-ray crystallography to serve a functional role in the 
binding association of Pel A and Lau to βI-tubulin (Prota, Bargsten et al. 2014). This study 
has provided biological evidence in support of this prediction through various measurement 
parameters, and has confirmed a functional role for D297 in the binding association of both 
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Pel A and Lau during induced microtubule-assembly. Although this role has been 
established, the significance of the D297 amino acid amid a number of other predicted 
binding interactions remains unclear. Within our laboratory, we seek to expand 
investigations into the role of specific amino acid residues, with preliminary investigations 
underway into Q293, V335, N339, Y342, Y312, F296 (Kanakkanthara, Sundberg Carson, 
unpublished data) – residues predicted to alter drug-protein interactions with either Pel A 
or Lau.  Further study of these predicted binding interactions is required in order assign a 
hierarchical weighting to the importance of each during the rational design of new synthetic 
analogues. 
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Chapter 4: Overall discussion and future directions 
4.1.1 Closing remarks 
The unique binding region of β-tubulin associated with novel MSAs Pel A and Lau has 
been thoroughly characterised as a novel pharmacophore through a large number of studies 
carried out over the last decade. This region represents a significant alternative to the taxane 
binding region for the development of novel MSAs, as compounds like Pel A and Lau 
demonstrate potentially advantageous properties in overcoming some of the clinical 
limitations of currently available MTAs. In order to continue advancement in the study of 
compounds that associate to this region, research must look toward the generation of a 
complete, mechanistic basis of understanding in the specific drug-residue interactions that 
lead to enhanced polymerisation dynamics in microtubules with these novel compounds. 
With these insights, the synthesis of highly specific molecules with fewer off-target 
interactions may finally come to fruition, improving medical outcomes for those affected 
by cancers that previously, may have lacked efficacious chemotherapeutic options. 
To continue our progress towards these goals, current research directions include a move 
towards highly specific investigations into the role of individual amino acid residues in the 
binding region in order to establish the functional significance of each interaction in the 
promotion of microtubule-assembly. Mutagenesis serves as a valuable tool for this purpose, 
and allows the examination of small, introduced changes in a protein target, such as β-
tubulin, to be assessed at the level of individual amino acids for perturbations in normal 
drug-responses. Classically, randomly introduced mutations conferring drug-resistance 
phenotypes to Pel A and Lau have been incredibly valuable in further characterisation in 
the binding region of these compounds (Begaye, Trostel et al. 2011, Kanakkanthara, 
Wilmes et al. 2011, Kanakkanthara, Eras et al. 2014), however the random nature of 
introduced genetic mutations in the presence of a drug or other mutagen can lead to drug-
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resistance phenotypes through mechanisms other than the introduction of a discrete 
mutation in the protein target of interest. Recently, the genetically amenable nature of S. 
cerevisiae has been utilised in a site-directed mutagenesis approach, finding introduced 
point mutations A298T, R308H, V335W and N339L in a humanised yeast β-tubulin 
sequence confer resistance to Pel A (Hanna, Maass et al. 2014). These particular mutations 
are located within the binding pocket of Pel A, and show that disruptions at these specific 
sites reduces drug-induced microtubule assembly. This puts these particular residues 
forward as candidate effectors of drug-binding; useful knowledge for developing drug-
analogues with functional enhancements to these residues. 
In the present study, we sought to move the investigation of single amino acid interactions 
with Pel A and Lau forward into mammalian cell lines, where physiological interactions 
may be more representative of how these compounds affect human cells. Emerging HDX-
MS data (Huzil, Chik et al. 2008, Khrapunovich-Baine, Menon et al. 2011), along with 
computational (Bennett, Barakat et al. 2010, Nguyen, Xu et al. 2010, Churchill, 
Klobukowski et al. 2014) and crystallographic (Prota, Bargsten et al. 2014) studies have 
generated insights that have allowed for the rational selection of individual amino acids to 
study, such as D297 as in the current  investigation. 
By introducing βI-tubulin containing the mutant D297I substitution to HEK293 cells within 
a transfected cell population, this study demonstrated a small but highly consistent drug 
resistance effect in these cells to both Pel A and Lau relative to tGFP-βI-tubulin transfected 
and WT HEK293 cells. Primary investigations revealed that the tGFP-βI-tubulin and tGFP-
D297I-tubulin mutant proteins were present in relatively low abundance in transfected 
HEK293 cultures, however populations with this mutation present were more resistant to 
Pel A and Lau. This raised questions regarding the true nature of mutant protein abundance 
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as discussed in earlier chapters, and warrants further assessment by alternative quantitative 
methods in order to better understand the significance of these observed changes in 
concentration-response of D297I-βI-tubulin transfected cells treated with either Pel A or 
Lau. 
Transfected cultures of both tGFP-βI-tubulin or tGFP-D297I-tubulin exhibited no 
significant concentration-response alterations under treatment with PTX or IXA, 
suggesting the biological function of mutant βI-tubulin subunits was not significantly 
different to that of WT βI-tubulin, and introduced mutations did not significantly hinder 
normal biological function through global 3-D conformational change in these proteins. 
tGFP-tagged βI-tubulin subunits were observed while incorporated within polymerised 
microtubule structures by live cell confocal microscopy, demonstrating these mutant 
components were actively involved in typical microtubule functions. The observed 
concentration-response shift of D297I substitution mutant-transfectants under treatment 
with Pel A or Lau was a small fold change, however this is may be the result of incomplete 
distribution of mutant D297I-βI-tubulin subunits throughout the total cell population. The 
data presented within this thesis suggest that the introduction of mutant D297I βI-tubulin 
by means of transfection allows for retention in dynamic-instability at a higher 
concentrations of Pel A or Lau. This implicates amino acid D297 of βI-tubulin as likely to 
be directly involved in the normal binding association of both Lau and Pel A in the region 
of the mutation. 
4.1.2 Future Directions 
In this investigation, the introduction of the mutant βI-tubulin isotype by means of transient 
transfection allowed the functional role of this particular mutation in Pel A and Lau binding 
to be evaluated, as seen through changes observed in concentration-response studies. As 
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the shift in response was a small fold-change, any further studies into the functional role of 
individual amino acids, if carried out utilising similar methodologies, have a need for 
adaptations to enhance the resolution of any detectable changes in concentration-response. 
Variations in the approach designed to improve the abundance of mutant βI-tubulin, or even 
replace endogenous βI-tubulin contributions entirely may result in the generation of highly 
resistant cells, such as those generated through clonal selection in the presence of drug 
(Begaye, Trostel et al. 2011). These improved models are likely to demonstrate larger shifts 
in concentration-response to drugs of interest. An improved model may allow for greater 
insight into the hierarchical nature of each amino acid-drug interactions importance during 
induced-stabilisation, guiding strategic design of future Pel A/Lau compound analogues. 
During this investigation, significant consideration was given to how such cell models 
would be developed. A useful first step would be towards the generation of a clonal sub-
population with stable integration of βI-tubulin sequence containing the point mutation of 
interest. This would allow the establishment of clonal cell lines, with mutant βI-tubulin 
sequence present throughout the entire population. Following the generation of these cells, 
further genetic manipulations may be of use in the knockdown of wild type β-tubulin 
sequence utilising emerging biotechnologies capable of doing this in mammalian cells. 
One particular approach for achieving gene silencing of the endogenous βI-tubulin content 
within cells may be through the application of promoter targeted shRNA knockdown 
techniques. RNA mediated knockdown traditionally utilises an RNA sequence with 
antisense homology to a target RNA transcript of interest, which is introduced to cells via 
expression from a transfected plasmid, or by directly transfecting the appropriate nucleic 
acid sequence itself, thus mimicking the endogenous regulation mechanisms of non-coding 
RNAi (Hannon 2002, Meister and Tuschl 2004). These sequences form double stranded 
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RNA molecules which are then targeted for degradation by Dicer and RISC associated 
regulatory mechanisms (for review see Tomari and Zamore (2005), Carthew and 
Sontheimer (2009)), leading to the degradation of RNA transcripts and suppression of a 
cells ability to produce the target protein of interest. In recent years, our growing 
understanding of the role of short non-coding RNA in epigenetic regulation has led to the 
development of a useful new tool for suppression of a target protein. It has been shown that 
shRNAs targeted to the promoter sequence of a target gene of interest can be utilised to 
induce long term epigenetic silencing in the target promoter element of mammalian cells. 
This occurs through the initiation of chromatin remodelling enzymes such as DNA 
methyltransferase Dnmt3A, Hystone deacetylase HDAC1, lysine methyltransferases 
KMT6 and KMT1C (for full review see Malecová and Morris (2010), Sibley, Seow et al. 
(2010), Roberts, Andaloussi et al. (2012)). This alternative approach, known as RNA 
mediated transcriptional gene silencing, was first reported in mammalian cells by Morris, 
Chan et al. (2004). Emergent applications in the silencing of highly active gene sequences  
such as demonstrated by the in vivo suppression of HIV-1 infection (Suzuki, Hattori et al. 
2013), demonstrates the potent capabilities of this technique as it moves into mainstream 
applications among our available gene silencing techniques (Ross and Kassir 2014). 
In the current study, traditional gene silencing by siRNA mediated knockdown is an 
inappropriate strategy as the RNA transcript of endogenous βI-tubulin sequence differs 
from our mutant βI-tubulin variant of interest in only a single point mutation. By utilising 
a transcriptional gene silencing approach in cells with a stable integration of a βI-tubulin 
mutant sequence of interest, shRNA guide sequence with homology to a unique sequence 
within the βI-tubulin promoter may be a useful mechanism through which to induce 
transcriptional gene silencing, as our mutant βI-tubulin sequences are under the 
transcriptional regulation of a viral promoter sequence and thus able to avoid mechanisms 
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of transcriptional gene silencing. This represents a potentially useful approach for 
increasing the resolution of concentration-response studies on individual βI-tubulin point 
mutants in mammalian cells, dependent on the level of transcriptional gene silencing 
induced within the population. In addition, approaching the knockdown of endogenous βI-
tubulin sequence utilising transcriptional gene silencing techniques represents a potentially 
low cost strategy in comparison to current genome editing techniques such as zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) or clustered 
regularly interspaced short palindromic repeat targeting by CRISPR associated proteins 
(CRISPR/Cas).  
Once developed, a method producing mutant βI-tubulin homodimers in high abundance 
would be advantageous for the verification of D297, or other interactions of interest, as 
contributors to stabilising βI-tubulin interactions with Pel A and Lau. Expanding the 
investigation of D297 to additional cell lines in any immediate investigations would be 
highly valuable in generating further supporting evidence for the biological role of D297 
in Pel A/Lau binding-associations. 
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Appendices 
Appendix A: General Recipes     
Acrylamide Gels for SDS-PAGE: 
10% resolving gel – preparation for two gels 
Milli-Q ddH2O 8.0 mL 
1.5 M Tris (pH to 8.8 by HCl) 5.0 mL 
10 % SDS 200.0 µL 
30 % bis-acrylamide 6.66 mL 
10 % APS 100.0 µL 
TEMED 10.0 µL 
(Overlay gel with 100 % isopropanol while setting) 
 
4 % Stacking gel – preparation for two gels 
Milli-Q ddH2O 6.1 mL 
1.5 M Tris (pH to 6.8 with conc. HCl) 2.5 mL 
10 % SDS 100.0 µL 
30 % bis-acrylamide 1.33 mL 
10 % APS 50.0 µL 
TEMED 
 
10.0 µL 
DNA Separation Gels – Preparation of single gel 
Agarose gel (1 %)   
Agarose 35.0 mg 
1 x TBE 
 
35.0 mL 
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Cell lysis buffers  
RIPA buffer (100 mL)   
1M Tris-HCL (pH 7.6) 2.5 mL 
NaCl 0.88 g   
EDTA 0.15 g 
SDS 0.1 g 
Triton X-100 1.0 mL 
Sodium deoxycholate 1.0 g 
(pH to 7.5)  
Dilute to 100 mL with Milli-Q ddH2O   
Hypotonic lysis buffer (1 L)  
1.0 mM MgCl 2 95.211 mg 
2.0 mM EGTA,  0.7607 g 
1% Nonidet P-40 1.0 mL 
50 mM Tris-HCl 6.057 g 
10 uL/mL protease inhibitor cocktail prior to lysis 
Dilute to 100 mL with Milli-Q ddH2O   
Colloidal Coomassie fixative (500 mL)  
50 % Ethanol 250.0 mL 
3.0 % Ortho-phosphoric acid  15.0 mL 
Dilute to 500 mL with Milli-Q ddH2O  
Colloidal Coomassie staining solution (500 mL) 
Coomassie brilliant blue G250 3.0 mg 
10 % Acetic acid 50.0 mL 
34 % Methanol 170.0 mL 
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17 % Ammonium sulphate 65.0 mL 
Dilute to 100 mL with Milli-Q ddH2O  
MTT Solution (50 mL)  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 250.0 mg 
1 x PBS to 50 mL  
Sterile filter and protect from light exposure. Kept sterile  
MTT solubilizer (500 mL)  
10 % SDS  50.0 g 
45 % N, N-DMF 225.0 mL 
Dilute to 500 mL with Milli-Q ddH2O  
pH adjusted to 4.5 using glacial acetic acid  
10 x PBS (1L)  
1.37 M NaCL 80.0 g 
0.16 M KCl 2.0 g 
0.101 M Na2HPO4 14.4 g 
0.18 M KH2PO4 2.4 g 
Dilute to 1 L with Mill-Q ddH2O  
pH adjusted to 7.4  
5 x Laemmli sample buffer (100 mL)  
4.0 M SDS 11.535 g 
6.1 M Glycerol 5.618 g 
0.22 M Tris-HCl (pH adjusted to 6.8) 0.347 g 
0.75 mM Bromophenol blue 5.024 mg 
Dilute to 100 mL with Milli-Q ddH2O  
10% β-mercaptoethanol by volume added immediately before use 
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10 x SDS running buffer (1L)  
SDS 10.0 g 
Tris-base  30.3 g 
Glycine 144.1g 
Dilute to 1 L with Milli-Q ddH2O   
Transfer buffer for Western blot (1L)  
Tris-base 
3.03 g 
 
Glycine 
14.4 g 
 
20 % Methanol 200 mL 
Dilute to 1 L with Milli-Q ddH2O  
Prepare fresh and chill to 4˚C prior to use  
5X TBE (Tris-borate EDTA) buffer (1L)  
 
 
450 mM Tris 54.0 g 
450 mM Boric acid 27.5 g 
10 mM EDTA 3.72 g 
Dilute to 1 L with Milli-Q ddH2O 
 
 
 
TBS  (1 L)  
50 mM Tris 6.0 g 
150 mM NaCl 8.76 g 
Dilute to 1 L with Milli-Q ddH2O  
pH to 7.5 with conc. HCl 
 
 
TBST (1 L)  
Tween-20 1.0 mL 
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Dilute to 1 L with TBS  
 
 
